var docs;if (!docs) docs =[]; docs["116"]={"11605":"<p><b>Title</b> Triazolam / Erythromycin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Erythromycin (Systemic) may increase the serum concentration of Triazolam. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider alternatives to the combination of triazolam and erythromycin. If combined, use extra caution and closer monitoring for excessive triazolam effects. Reduced triazolam doses may be necessary.</p> \n<p><b>Discussion</b> In a cross-over study of 16 healthy volunteers, erythromycin (333 mg three times daily for 3 days) increased the triazolam AUC 51% and decreased the clearance 52%.<sup>1</sup> In another cross-over trial of 12 healthy volunteers, erythromycin (500 mg twice daily for 2 days) increased the triazolam (0.125 mg single dose) AUC 280% and decreased the clearance 68%.<sup>2</sup> In a double-blind study of 57 healthy volunteers, mild mental status changes suggestive of enhanced triazolam effects were observed in subjects who received triazolam (0.25 mg daily) and erythromycin (750 mg daily) compared with subjects who received triazolam and placebo.<sup>3</sup> Additionally, a case report describes a 63-year-old male with chronic renal failure who experienced hallucinations with the concurrent use of triazolam and erythromycin.<sup>4</sup><br><br>Triazolam prescribing information advises exercising caution when using triazolam with CYP3A4 enzyme inhibitors.<sup>5</sup><br><br>The mechanism of this interaction is likely due to erythromycin-mediated inhibition of CYP3A4, an enzyme responsible for triazolam metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Phillips JP, Antal EJ, Smith RB. A pharmacokinetic drug interaction between erythromycin and triazolam. <i>J Clin Psychopharmacol</i>. 1986;6(5):297-299. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3771812\">[PubMed 3771812]</a></p>\n<p>2. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. <i>Clin Pharmacol Ther</i>. 1998;64(3):278-285. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9757151\">[PubMed 9757151]</a></p>\n<p>3. Mattila MJ, Idanpaan-Heikkila JJ, Tornwall M, Vanakoski J. Oral single doses of erythromycin and roxithromycin may increase the effects of midazolam on human performance. <i>Pharmacol Toxicol</i>. 1993;73(3):180-185. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8265524\">[PubMed 8265524]</a></p>\n<p>4. Tokinaga N, Kondo T, Kaneko S, Otani K, Mihara K, Morita S. Hallucinations after a therapeutic dose of benzodiazepine hypnotics with co-administration of erythromycin. <i>Psychiatry Clin Neurosci</i>. 1996;50(6):337-339. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9014234\">[PubMed 9014234]</a></p>\n<p>5. Halcion (triazolam) [prescribing information]. Peapack, NJ: Greentone LLC; September 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11606":"<p><b>Title</b> Copanlisib / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Copanlisib. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> If concomitant use of copanlisib and strong CYP3A4 inhibitors cannot be avoided, reduce the copanlisib dose to 45 mg. Monitor patients for increased copanlisib effects/toxicities.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of patients with cancer described in the prescribing information, itraconazole (200 mg daily for 10 days) increased the copanlisib (60 mg single IV dose) AUC 53%.<sup>1</sup> The maximum serum concentration of copanlisib was unchanged.<sup>1</sup><br><br>The copanlisib prescribing information states that concomitant use of copanlisib with strong CYP3A4 inhibitors increases the copanlisib AUC and the risk of adverse effect.<sup>1</sup> If concomitant use with strong CYP3A4 inhibitors cannot be avoided, reduce the copanlisib dose to 45 mg.<sup>1</sup><br><br>The mechanism of this interaction is likely due to itraconazole-mediated inhibition of CYP3A4, an enzyme responsible for copanlisib metabolism. Itraconazole-mediated inhibition of P-glycoprotein and/or BCRP, transporters responsible for copanlisib disposition, may also contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Aliqopa (copanlisib) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; September 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11607":"<p><b>Title</b> Copanlisib / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Copanlisib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of copanlisib and strong CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of patients with cancer described in the prescribing information, rifampin (600 mg daily for 12 days) decreased the copanlisib (60 mg single IV dose) AUC and maximum serum concentration 63% and 15%, respectively.<sup>1</sup><br><br>Copanlisib prescribing information states that because use of copanlisib with strong CYP3A4 inducers may decrease copanlisib concentrations, concomitant use of these agents should be avoided.<sup>1</sup><br><br>The mechanism of this interaction is likely due to rifampin-mediated induction of CYP3A4, an enzyme responsible for copanlisib metabolism. Rifampin induction of P-glycoprotein, a transporter involved in copanlisib disposition, may also contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Aliqopa (copanlisib) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; September 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11608":"<p><b>Title</b> Copanlisib / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Copanlisib. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of copanlisib and St. John's wort.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of patients with cancer described in the prescribing information, the strong CYP3A4 inducer rifampin (600 mg daily for 12 days) decreased the copanlisib (60 mg single IV dose) AUC and maximum serum concentration 63% and 15%, respectively.<sup>1</sup><br><br>Copanlisib prescribing information states that because use of copanlisib with strong CYP3A4 inducers may decrease copanlisib concentrations, concomitant use of these agents should be avoided.<sup>1</sup> Although copanlisib prescribing information lists St. John's wort as an example of a strong CYP3A4 inducer, the majority of the clinical data suggest it is a moderate CYP3A4 inducer.<sup>2,3,4,5</sup><br><br>The mechanism of this interaction is likely due to rifampin-mediated induction of CYP3A4, an enzyme responsible for copanlisib metabolism. Rifampin induction of P-glycoprotein, a transporter involved in copanlisib disposition, may also contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Aliqopa (copanlisib) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; September 2017.</p>\n<p>2. Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. <i>Clin Pharmacol Ther</i>. 2003;73(1):41-50. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12545142\">[PubMed 12545142]</a></p>\n<p>3. Sugimoto K, Ohmori M, Tsuruoka S, et al. Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin. <i>Clin Pharmacol Ther</i>. 2001;70(6):518-524. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11753267\">[PubMed 11753267]</a></p>\n<p>4. Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. <i>Clin Pharmacol Ther</i>. 2001;70(4):317-326. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11673747\">[PubMed 11673747]</a></p>\n<p>5. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John's wort [published correction appears in <i>Lancet</i> 2001;355(9263):1210]. <i>Lancet</i>. 2000;355(9203):547-548. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10683007\">[PubMed 10683007]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11609":"<p><b>Title</b> Copanlisib / DilTIAZem</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> DilTIAZem may increase the serum concentration of Copanlisib. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients for increased copanlisib effects/toxicities if combined with diltiazem. Consider reducing the copanlisib dose to 45 mg.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of patients with cancer described in the prescribing information, the strong CYP3A4 inhibitor itraconazole (200 mg daily for 10 days) increased the copanlisib (60 mg single IV dose) AUC 53%.<sup>1</sup> The maximum serum concentration of copanlisib was unchanged.<sup>1</sup><br><br>The copanlisib prescribing information states that concomitant use of copanlisib with strong CYP3A4 inhibitors increases the copanlisib AUC and the risk of adverse effect.<sup>1</sup> If concomitant use with strong CYP3A4 inhibitors cannot be avoided, reduce the copanlisib dose to 45 mg.<sup>1</sup> Although copanlisib prescribing information lists diltiazem as a strong CYP3A4 inhibitor, the majority of the clinical data suggest that diltiazem is a moderate CYP3A4 inhibitor.<sup>2,3,4</sup> <br><br>The mechanism of this interaction is likely due to itraconazole-mediated inhibition of CYP3A4, an enzyme responsible for copanlisib metabolism. Itraconazole-mediated inhibition of P-glycoprotein and/or BCRP, transporters responsible for copanlisib disposition, may also contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Aliqopa (copanlisib) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; September 2017.</p>\n<p>2. Varhe A, Olkkola KT, Neuvonen PJ. Diltiazem enhances the effects of triazolam by inhibiting its metabolism. <i>Clin Pharmacol Ther</i>. 1996;59(4):369-375. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8612379\">[PubMed 8612379]</a></p>\n<p>3. Backman JT, Olkkola KT, Aranko K, Himberg JJ, Neuvonen P. Dose of midazolam should be reduced during diltiazem and verapamil treatments. <i>Br J Clin Pharmacol</i>. 1994;37(3):221-225. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8198928\">[PubMed 8198928]</a></p>\n<p>4. Cardizem (diltiazem) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; November 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11610":"<p><b>Title</b> Copanlisib / Conivaptan</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Conivaptan may increase the serum concentration of Copanlisib. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients for increased copanlisib effects/toxicities if combined with conivaptan. Consider reducing the copanlisib dose to 45 mg.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of patients with cancer described in the prescribing information, the strong CYP3A4 inhibitor itraconazole (200 mg daily for 10 days) increased the copanlisib (60 mg single IV dose) AUC 53%.<sup>1</sup> The maximum serum concentration of copanlisib was unchanged.<sup>1</sup><br><br>The copanlisib prescribing information states that concomitant use of copanlisib with strong CYP3A4 inhibitors increases the copanlisib AUC and the risk of adverse effect.<sup>1</sup> If concomitant use with strong CYP3A4 inhibitors cannot be avoided, reduce the copanlisib dose to 45 mg.<sup>1</sup> Although copanlisib prescribing information lists conivaptan as a strong CYP3A4 inhibitor, the majority of the clinical data suggest conivaptan is a moderate CYP3A4 inhibitor.<sup>2</sup> <br><br>The mechanism of this interaction is likely due to itraconazole-mediated inhibition of CYP3A4, an enzyme responsible for copanlisib metabolism. Itraconazole-mediated inhibition of P-glycoprotein and/or BCRP, transporters responsible for copanlisib disposition, may also contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Aliqopa (copanlisib) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; September 2017.</p>\n<p>2. Vaprisol (conivaptan) [prescribing information]. Nashville TN: Cumberland Pharmaceuticals Inc; October 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11611":"<p><b>Title</b> Copanlisib / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Copanlisib. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of patients with cancer described in the prescribing information, the strong CYP3A4 inhibitor itraconazole (200 mg daily for 10 days) increased the copanlisib (60 mg single IV dose) AUC 53%.<sup>1</sup> The maximum serum concentration of copanlisib was unchanged.<sup>1</sup><br><br>The copanlisib prescribing information states that concomitant use of copanlisib with strong CYP3A4 inhibitors increases the copanlisib AUC and the risk of adverse effect.<sup>1</sup> If concomitant use with strong CYP3A4 inhibitors cannot be avoided, reduce the copanlisib dose to 45 mg.<sup>1</sup> Although copanlisib prescribing information lists grapefruit juice as a strong CYP3A4 inhibitor, the majority of the clinical data suggest that grapefruit juice is a moderate CYP3A4 inhibitor.<sup>2,3,4,5</sup> Additionally, because grapefruit juice inhibits intestinal CYP3A4 but has little effect on hepatic CYP3A4, it is unlikely to affect concentrations of copanlisib, a drug that is administered intravenously.<sup>2,3,4,5</sup><br><br>The mechanism of this interaction is likely due to itraconazole-mediated inhibition of CYP3A4, an enzyme responsible for copanlisib metabolism. Itraconazole-mediated inhibition of P-glycoprotein and/or BCRP, transporters responsible for copanlisib disposition, may also contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Aliqopa (copanlisib) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; September 2017.</p>\n<p>2. Lundahl J, Regardh CG, Edgar B, Johnsson G. Effects of grapefruit juice ingestion--pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. <i>Eur J Clin Pharmacol</i>. 1997;52(2):139-145. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9174684\">[PubMed 9174684]</a></p>\n<p>3. Kupferschmidt HH, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S. Interaction between grapefruit juice and midazolam in humans. <i>Clin Pharmacol Ther</i>. 1995;58(1):20-28. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7628179\">[PubMed 7628179]</a></p>\n<p>4. Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. <i>J Clin Invest</i>. 1997;99(10):2545-2553. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9153299\">[PubMed 9153299]</a></p>\n<p>5. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. <i>Clin Pharmacol Ther</i>. 2003;74(2):121-129. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12891222\">[PubMed 12891222]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11612":"<p><b>Title</b> Iron Salts / Iron Isomaltoside</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Iron Isomaltoside may decrease the serum concentration of Iron Salts. Specifically, absorption of oral iron salts may be reduced. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Do not administer intravenous (IV) iron isomaltoside with other oral iron salts. Therapy with oral iron salts should begin 5 days after the last dose of IV iron isomaltoside.</p>\n<div>\n <p><b>Iron Salts Interacting Members</b> Ferrous Fumarate, Ferrous Gluconate, Ferrous Sulfate, Iron Acetyltransferrin, Polysaccharide-Iron Complex, Sodium Feredetate<br><b>Exceptions</b> Ferric Carboxymaltose, Ferric Citrate, Ferric Gluconate, Ferric Hydroxide Polymaltose Complex, Ferric Pyrophosphate Citrate, Ferumoxytol, Iron Dextran Complex, Iron Isomaltoside, Iron Sucrose</p>\n</div> \n<p><b>Discussion</b> Iron isomaltoside product labeling states that it should not be administered concomitantly with oral iron preparations as the absorption of oral iron is reduced.<sup>1</sup> Oral iron therapy should not begin until at least 5 days after the last iron isomaltoside injection.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Monofer (iron isomaltoside) [UK summary of product characteristics]. Holbaek, Denmark: Pharmacosmos A/S; May 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11613":"<p><b>Title</b> Aminoglycosides / Ataluren</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ataluren may enhance the adverse/toxic effect of Aminoglycosides. Specifically, an increased risk of nephrotoxicity may occur with the concomitant use of ataluren and aminoglycosides. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid the concomitant use of ataluren and intravenous aminoglycosides due to an increased risk of nephrotoxicity.</p>\n<div>\n <p><b>Aminoglycosides Interacting Members</b> Amikacin, Arbekacin, Gentamicin (Systemic), Isepamicin, Kanamycin, Neomycin, Streptomycin, Tobramycin (Systemic)</p>\n</div> \n<p><b>Discussion</b> A phase 3 clinical trial of ataluren for the treatment of nonsense mutation cystic fibrosis reported cases of severe and life threatening acute kidney injury with the concomitant use of ataluren (40 mg/kg/day in divided doses) and intravenous aminoglycoside therapy.<sup>1</sup> All cases were resolved with the discontinuation of aminoglycoside therapy. Approximately 7 months into the 27-month trial, study protocol was amended to encourage subjects to maintain adequate hydration and prohibit systemic aminoglycoside use within 2 weeks of ataluren therapy. No further incidences of nephrotoxicity were witnessed after the protocol changes. <br><br>The product labels for ataluren state that the coadministration of ataluren and systemic aminoglycosides is contraindicated due to an increased risk of nephrotoxicity.<sup>2</sup> If treatment with intravenous aminoglycosides is necessary, ataluren should be discontinued and resumed at minimum 2 days after aminoglycoside use has ceased.<br><br>The mechanism of this potential interaction is not known, but ataluren may potentiate the nephrotoxic effects of aminoglycosides.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kerem E, Konstan MW, De Boeck K, et al; Cystic Fibrosis Ataluren Group. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Respir Med</i>. 2014;2(7):539-547. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24836205\">[PubMed 24836205]</a></p>\n<p>2. Translarna (ataluren) [summary of product characteristics]. Dublin, Ireland: PTC Therapeutics International Limited; January 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11614":"<p><b>Title</b> Mifamurtide / Corticosteroids (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Corticosteroids (Systemic) may diminish the therapeutic effect of Mifamurtide. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of mifamurtide and chronic/routine use of corticosteroids.</p>\n<div>\n <p><b>Corticosteroids (Systemic) Interacting Members</b> Beclomethasone (Systemic), Betamethasone (Systemic), Corticotropin, Cortisone, Deflazacort, Dexamethasone (Systemic), Fludrocortisone, Hydrocortisone (Systemic), MethylPREDNISolone, PrednisoLONE (Systemic), PredniSONE, Triamcinolone (Systemic)</p>\n</div> \n<p><b>Discussion</b> Mifamurtide product labeling states that concomitant use of mifamurtide and the chronic/routine use of corticosteroids should be avoided.<sup>1</sup> This recommendation is based on the hypothesis that corticosteroids are immunosuppressants and may inhibit mifamurtide-mediated stimulation of macrophage and mononuclear phagocytic function, thus reducing mifamurtide efficacy.<sup>1</sup> The effect of corticosteroids on mifamurtide efficacy has not been studied in humans.</p> \n<p><b>Footnotes</b> </p>\n<p>1. MEPACT (mifamurtide) [summary of product characteristics]. Puteaux, France: Takeda France SAS; December 2013.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11615":"<p><b>Title</b> Mifamurtide / Nonsteroidal Anti-Inflammatory Agents</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dose</b>: Mifamurtide is specifically contraindicated with high-dose nonsteroidal anti-inflammatory agents.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Mifamurtide. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid use of mifamurtide and high-dose nonsteroidal anti-inflammatory drugs (NSAIDs). This combination is listed as a contraindication in mifamurtide product labeling.</p>\n<div>\n <p><b>Nonsteroidal Anti-Inflammatory Agents Interacting Members</b> Aceclofenac, Acemetacin, Celecoxib, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, Flurbiprofen (Systemic), Ibuprofen, Ibuprofen (Topical), Indomethacin, Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), Lornoxicam, Loxoprofen, Meclofenamate, Mefenamic Acid, Meloxicam, Morniflumate, Nabumetone, Naproxen, Nimesulide, Oxaprozin, Parecoxib, Pelubiprofen, Phenylbutazone, Piroxicam (Systemic), Piroxicam (Topical), Propyphenazone, Sulindac, Talniflumate, Tenoxicam, Tiaprofenic Acid, Tolfenamic Acid, Tolmetin, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> Concomitant use of mifamurtide and high-dose nonsteroidal anti-inflammatory drugs (NSAIDs) is contraindicated in mifamurtide product labeling.<sup>1</sup> This recommendation is based on in vitro data showing that NSAIDs may inhibit mifamurtide-mediated stimulation of macrophage and mononuclear phagocytic function, thereby reducing the therapeutic effect of mifamurtide.<sup>2</sup> In another in vitro study, mifamurtide activation of monocytes was preserved in cell lines when ibuprofen concentrations remained low (equivalent to ibuprofen 200 mg).<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. MEPACT (mifamurtide) [summary of product characteristics]. Puteaux, France: Takeda France SAS; December 2013.</p>\n<p>2. Fedorocko P, Hoferova Z, Hofer M, Brezani P. Administration of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) and diclofenac in the combination attenuates their anti-tumor activities. <i>Neoplasma</i>. 2003;50(3):176-184. [PubMed: 12937850]</p>\n<p>3. Fujimaki W, Griffin JR, Kleinerman ES. Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation? <i>Cancer Immunol Immunother</i>. 1993;36(1):45-51. [PubMed: 8422667]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11616":"<p><b>Title</b> Mifamurtide / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may diminish the therapeutic effect of Mifamurtide. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid use of mifamurtide and cyclosporine. This combination is listed as a contraindication in mifamurtide product labeling.</p> \n<p><b>Discussion</b> Concomitant use of mifamurtide and cyclosporine is contraindicated in mifamurtide product labeling.<sup>1</sup> This recommendation is based on the hypothesis that calcineurin inhibitors may inhibit mifamurtide-mediated stimulation of macrophage and mononuclear phagocytic function, thus reducing mifamurtide efficacy.<sup>1</sup> The effect of calcineurin inhibitors on mifamurtide efficacy has not been studies in humans, but in mice, cyclosporine use had no effect on mifamurtide-mediated macrophage activation.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. MEPACT (mifamurtide) [summary of product characteristics]. Puteaux, France: Takeda France SAS; December 2013.</p>\n<p>2. LeGrue SJ, Saiki I, Romerdahl CA, Fidler IJ. Systemic macrophage activation by liposomes containing MTP-PE in mice immunosuppressed with cyclosporine. <i>Transplantation</i>. 1987;43(4):584-586. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3576675\">[PubMed 3576675]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11617":"<p><b>Title</b> Mifamurtide / Tacrolimus (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tacrolimus (Systemic) may diminish the therapeutic effect of Mifamurtide. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid use of mifamurtide and tacrolimus. This combination is listed as a contraindication in mifamurtide product labeling.</p> \n<p><b>Discussion</b> Concomitant use of mifamurtide and tacrolimus is contraindicated in mifamurtide product labeling.<sup>1</sup> This recommendation is based on the hypothesis that calcineurin inhibitors may inhibit mifamurtide-mediated stimulation of macrophage and mononuclear phagocytic function, thus reducing mifamurtide efficacy.<sup>1</sup> The effect of calcineurin inhibitors on mifamurtide efficacy has not been studies in humans, but in mice, cyclosporine use had no effect on mifamurtide-mediated macrophage activation.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. MEPACT (mifamurtide) [summary of product characteristics]. Puteaux, France: Takeda France SAS; December 2013.</p>\n<p>2. LeGrue SJ, Saiki I, Romerdahl CA, Fidler IJ. Systemic macrophage activation by liposomes containing MTP-PE in mice immunosuppressed with cyclosporine. <i>Transplantation</i>. 1987;43(4):584-586. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3576675\">[PubMed 3576675]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11618":"<p><b>Title</b> Adefovir / Ataluren</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ataluren may increase the serum concentration of Adefovir. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients for increased adefovir effects and/or toxicity during concomitant ataluren use.</p> \n<p><b>Discussion</b> Adefovir exposure was 60% higher in the presence of ataluren according to a clinical study referenced in the ataluren summary of product characteristics.<sup>1</sup> Caution is advised when adefovir is used concomitantly with ataluren.<br><br>The likely mechanism of this proposed interaction is ataluren-mediated inhibition of OAT1, a transporter responsible for the active renal tubular excretion of adefovir<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Translarna (ataluren) [summary of product characteristics]. Dublin, Ireland: PTC Therapeutics International Limited; January 2017.</p>\n<p>2. Maeda K, Tian Y, Fujita T, et al. Inhibitory effects of p-aminohippurate and probenecid on the renal clearance of adefovir and benzylpenicillin as probe drugs for organic anion transporter (OAT) 1 and OAT3 in humans. <i>Eur J Pharm Sci</i>. 2014;59:94-103. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24747579\">[PubMed 24747579]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11619":"<p><b>Title</b> Ataluren / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> RifAMPin may decrease the serum concentration of Ataluren. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients for decreased ataluren effects during concomitant rifampin use.</p> \n<p><b>Discussion</b> Ataluren exposure was decreased 30% in the presence of rifampin according to a clinical study referenced in the ataluren summary of product characteristics.<sup>1</sup> Caution is advised when ataluren is used concomitantly with rifampin.<br><br>The likely mechanism of this proposed interaction is rifampin-mediated induction of UGT1A9, an enzyme responsible for ataluren metabolism.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Translarna (ataluren) [summary of product characteristics]. Dublin, Ireland: PTC Therapeutics International Limited; January 2017.</p>\n<p>2. Soars MG, Petullo DM, Eckstein JA, et al. An assessment of udp-glucuronosyltransferase induction using primary human hepatocytes. <i>Drug Metab Dispos</i>. 2004;32(1):140-148. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14709631\">[PubMed 14709631]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11620":"<p><b>Title</b> Vitamin K Antagonists / Orlistat</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Orlistat may enhance the anticoagulant effect of Vitamin K Antagonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased effects of vitamin K antagonists (ie, bleeding, increased INR) if orlistat is initiated in a vitamin K antagonist treated patient.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> A single case report describes a warfarin-stable patient who experienced an increase INR 18 days after the addition of orlistat to his regimen. Subsequent doses were held and then restarted at a reduced warfarin dosage to maintain an acceptable INR.<sup>1</sup> <br><br>In contrast, the pharmacokinetics of racemic warfarin (30 mg single oral dose) were essentially unaltered in 12 normal subjects when administered on the day 11 of a 16-day course of orlistat (120 mg 3 times/day).<sup>2</sup> No changes in INR were detected. Serum concentrations of vitamin K and its epoxide were also unaltered.<sup>2</sup> <br><br>Prescribing information for orlistat states that patients who are on chronic stable doses of warfarin who are prescribed orlistat should be monitored closely for changes in coagulation parameters due to the possible decrease in vitamin K absorption.<sup>3</sup> The prescribing information for phenindione also states that orlistat may decrease vitamin K absorption and enhance the effects of vitamin K antagonists.<sup>4</sup><br><br>The mechanism of this potential interaction has not been fully investigated. Although the pharmacokinetics of warfarin appear unchanged by orlistat, dietary adjustments (eg, lower fat meals) and potential reductions in the absorption of fat-soluble vitamins (vitamin K in particular), may lead to increased warfarin effects and an increased INR.</p> \n<p><b>Footnotes</b> </p>\n<p>1. MacWalter RS, Fraser HW, Armstrong KM. Orlistat enhances warfarin effect. <i>Ann Pharmacother</i>. 2003;37(4):510-512. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12659605\">[PubMed 12659605]</a></p>\n<p>2. Zhi J, Melia AT, Guerciolini R, et al. The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. <i>J Clin Pharmacol</i>. 1996;36(7):659-666. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8844450\">[PubMed 8844450]</a></p>\n<p>3. Xenical (orlistat) [prescribing information]. South San Francisco, CA: Genentech USA Inc; August 2015.</p>\n<p>4. Dindevan (phenindione) [summary of product characteristics]. London, UK: Mercury Pharma Group Ltd; September 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11621":"<p><b>Title</b> Lipegfilgrastim / Antineoplastic Agents</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.</p>\n<div>\n <p><b>Antineoplastic Agents Interacting Members</b> Altretamine, Amsacrine, AzaCITIDine, Belotecan, Bendamustine, Bleomycin, Busulfan, Cabazitaxel, Capecitabine, CARBOplatin, Carmustine, Chlorambucil, CISplatin, Cladribine, Clofarabine, Cyclophosphamide, Cytarabine (Conventional), Dacarbazine, DACTINomycin, DAUNOrubicin (Conventional), DAUNOrubicin (Liposomal), Decitabine, DOCEtaxel, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), EpiRUBicin, EriBULin, Estramustine, Etoposide, Etoposide Phosphate, Floxuridine, Fludarabine, Fluorouracil (Systemic), Fotemustine, Gemcitabine, Hydroxyurea, IDArubicin, Ifosfamide, Irinotecan (Conventional), Irinotecan (Liposomal), Ixabepilone, Lomustine, Mechlorethamine (Systemic), Melphalan, Mercaptopurine, Methotrexate, MitoMYcin (Systemic), MitoXANTRONE, Nelarabine, Oxaliplatin, PACLitaxel (Conventional), PACLitaxel (Protein Bound), PEMEtrexed, Pentostatin, Pixantrone, PRALAtrexate, Procarbazine, Raltitrexed, Streptozocin, Tegafur, Temozolomide, Teniposide, Thioguanine, Thiotepa, Topotecan, Trabectedin, Treosulfan, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vindesine, Vinflunine, Vinorelbine</p>\n</div> \n<p><b>Discussion</b> Lipegfilgrastim product labeling states that the safety and efficacy of lipegfilgrastim administered on the same day as myelosuppressive cytotoxic chemotherapy has not been established.<sup>1,2</sup> Since rapidly dividing myeloid cells (ie, those stimulated by use of lipegfilgrastim) are particularly sensitive to the effects of myelosuppressive cytotoxic chemotherapy, the use of lipegfilgrastim should not precede or overlap the administration of cytotoxic chemotherapy.<sup>1,2</sup> It is recommended that lipegfilgrastim should start at least 24 hours after the completion of chemotherapy.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lonquex (lipegfilgrastim) [summary of product characteristics]. Harlow, Essex, UK: Teva Pharma BV; June 2015.</p>\n<p>2. Lonquex (lipegfilgrastim) [summary of product characteristics]. Macquarie Park, New South Wales, Australia: Teva Pharmac Australia Pty Ltd; November 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11622":"<p><b>Title</b> Cyclophosphamide / Lipegfilgrastim</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Lipegfilgrastim may enhance the adverse/toxic effect of Cyclophosphamide. Specifically, the risk of pulmonary toxicity may be increased. Cyclophosphamide may diminish the therapeutic effect of Lipegfilgrastim. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of lipegfilgrastim and cyclophosphamide. Lipegfilgrastim should be administered at least 24 hours after the completion of cyclophosphamide. Consider monitoring for enhanced pulmonary toxicity when cyclophosphamide and lipegfilgrastim are given in combination.</p> \n<p><b>Discussion</b> Lipegfilgrastim product labeling states that the safety and efficacy of lipegfilgrastim administered on the same day as myelosuppressive cytotoxic chemotherapy, such as cyclophosphamide, has not been established.<sup>1,2</sup> Since rapidly dividing myeloid cells (ie, those stimulated by use of lipegfilgrastim) are particularly sensitive to the effects of myelosuppressive cytotoxic chemotherapy, the use of lipegfilgrastim should not precede or overlap the administration of cytotoxic chemotherapy.<sup>1,2</sup> It is recommended that lipegfilgrastim should start at least 24 hours after the completion of chemotherapy.<sup>1,2</sup><br><br>In addition to reduced lipegfilgrastim efficacy, the combined use of cyclophosphamide and lipegfilgrastim may increase the risk for pulmonary toxicity. Cyclophosphamide US prescribing information warns that its use in combination with a granulocyte colony-stimulating factor (ie, lipegfilgrastim) may increase the risk of pulmonary toxicity.<sup>3,4</sup> Several published reports describe pulmonary toxicity, sometimes severe or fatal, occurring in patients given colony-stimulating factors during treatment with chemotherapeutic regimens including cyclophosphamide.<sup>5,6,7</sup> The mechanism of this possible interaction is not clear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lonquex (lipegfilgrastim) [summary of product characteristics]. Harlow, Essex, UK: Teva Pharma BV; June 2015.</p>\n<p>2. Lonquex (lipegfilgrastim) [summary of product characteristics]. Macquarie Park, New South Wales, Australia: Teva Pharmac Australia Pty Ltd; November 2015.</p>\n<p>3. Cyclophosphamide [prescribing information]. Columbus, OH: Roxane Laboratories Inc; September 2013.</p>\n<p>4. Cyclophosphamide [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; May 2013.</p>\n<p>5. Couderc LJ, Stelianides S, Frachon I, et al. Pulmonary toxicity of chemotherapy and G/GM-CSF: a report of five cases. <i>Respir Med</i>. 1999;93(1):65-68. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10464852\">[PubMed 10464852]</a></p>\n<p>6. Yokose N, Ogata K, Tamura H, et al. Pulmonary toxicity after granulocyte colony-stimulating factor-combined chemotherapy for non-Hodgkin's lymphoma. <i>Br J Cancer</i>. 1998;77(12):2286-2290. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9649147\">[PubMed 9649147]</a></p>\n<p>7. Lei KI, Leung WT, Johnson PJ. Serious pulmonary complications in patients receiving recombinant granulocyte colony-stimulating factor during BACOP chemotherapy for aggressive non-Hodgkin's lymphoma. <i>Br J Cancer</i>. 1994;70(5):1009-1013. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7524599\">[PubMed 7524599]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11623":"<p><b>Title</b> Bleomycin / Lipegfilgrastim</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Lipegfilgrastim may enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased. Bleomycin may diminish the therapeutic effect of Lipegfilgrastim. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of lipegfilgrastim and bleomycin. Lipegfilgrastim should be administered at least 24 hours after the completion of bleomycin. Consider monitoring for enhanced pulmonary toxicity when bleomycin and lipegfilgrastim are given in combination.</p> \n<p><b>Discussion</b> Lipegfilgrastim product labeling states that the safety and efficacy of lipegfilgrastim administered on the same day as myelosuppressive cytotoxic chemotherapy, such as bleomycin, has not been established.<sup>1,2</sup> Since rapidly dividing myeloid cells (ie, those stimulated by use of lipegfilgrastim) are particularly sensitive to the effects of myelosuppressive cytotoxic chemotherapy, the use of lipegfilgrastim should not precede or overlap the administration of cytotoxic chemotherapy.<sup>1,2</sup> It is recommended that lipegfilgrastim should start at least 24 hours after the completion of chemotherapy.<sup>1,2</sup><br><br>In addition to reduced lipegfilgrastim efficacy, the combined use of bleomycin and lipegfilgrastim may increase the risk for pulmonary toxicity. According to one report, evidence of possible bleomycin-associated pulmonary toxicity was observed in 4 of 5 patients receiving G-CSF in combination with the ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy regimen.<sup>3</sup> The authors considered this noteworthy due to the unusually high rate of toxicity, particularly since the patients with evidence of toxicity received more than 5-fold lower doses of bleomycin that that normally associated with risk of pulmonary toxicity. Another case report describes a patient with rapidly-developing and fatal pulmonary toxicity attributed to concurrent use of bleomycin and G-CSF.<sup>4</sup><br><br>A retrospective analysis of 141 bleomycin-treated patients, 25 (18%) of whom experience bleomycin-associated pulmonary toxicity, similarly identified concurrent G-CSF use as a potential risk factor for pulmonary toxicity.<sup>5</sup> Among patients with pulmonary toxicity, 76% received G-CSF vs. only 47% of bleomycin recipients without pulmonary toxicity (p = 0.014). Increased age and use of the ABVD chemotherapy regimen were also identified as potential risk factors in the univariate analysis; due to the relatively small number of cases available, no multivariate analyses were reported. Several animal studies also support the association between G-CSF (or GM-CSF) use and a greater risk for bleomycin pulmonary toxicity.<sup>6,7,8</sup><br><br>In contrast, one comparison of the rates of bleomycin toxicity reported a similar rate of toxicity among both 29 patients treated with bleomycin plus G-CSF and 57 patients treated with bleomycin, etoposide, and cisplatin (but no G-CSF) (34% vs. 33%, respectively).<sup>9</sup><br><br>Additional data from studies designed to specifically address this issue are needed in order to definitively characterize this purported interaction, but the data currently available seem sufficient to justify greater caution when considering the concurrent use of bleomycin with either G-CSF or GM-CSF.<br><br>The exact mechanism(s) by which this combination may increase the risk of pulmonary toxicity is not certain, but an increase in granulocyte function and/or number due to G-CSF/GM-CSF administration is suspected.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lonquex (lipegfilgrastim) [summary of product characteristics]. Harlow, Essex, UK: Teva Pharma BV; June 2015.</p>\n<p>2. Lonquex (lipegfilgrastim) [summary of product characteristics]. Macquarie Park, New South Wales, Australia: Teva Pharmac Australia Pty Ltd; November 2015.</p>\n<p>3. Matthews JH. Pulmonary toxicity of ABVD chemotherapy and G-CSF in Hodgkin’s disease: possible synergy. <i>Lancet</i>. 1993;342(8877):988. [PMID: 7692199]</p>\n<p>4. Dirix LY, Schrijvers D, Druwe P, Van den Brande J, Verhoeven D, Van Oosterom AT. Pulmonary toxicity and bleomycin. <i>Lancet</i>. 1994;344(8914):56. [PMID: 7516990]</p>\n<p>5. Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. <i>J Clin Oncol</i>. 2005;23(30):7614-7620. [PMID: 16186594]</p>\n<p>6. Adachi K, Suzuki M, Sugimoto T, Uetsuka K, Nakamaya H, Doi K. Effects of granulocyte colony-stimulating factor on the kinetics of inflammatory cells in the peripheral blood and pulmonary lesions during the development of bleomycin-induced lung injury in rats. <i>Exp Toxicol Pathol</i>. 2003;55(1):21-32. [PMID: 12940625]</p>\n<p>7. Adach K, Suzuki M, Sugimoto T, et al. Granulocyte colony-stimulating factor exacerbates the acute lung injury and pulmonary fibrosis induced by intratracheal administration of bleomycin in rats. <i>Exp Toxicol Pathol</i>. 2002;53(6):501-510. [PMID: 11926293]</p>\n<p>8. Andreutti D, Gabbiani G, Neuville P. Early granulocyte-macrophage colony-stimulating factor expression by alveolar inflammatory cells during bleomycin-induced rat lung fibrosis. <i>Lab Invest</i>. 1998;78(12):1493-1502. [PMID: 9881949]</p>\n<p>9. Saxman SB, Nichols CR, Einhorn LH. Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor. <i>Chest</i>. 1997;111(3):657-660. [PMID: 9118704]</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11624":"<p><b>Title</b> Valbenazine / Tetrabenazine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Tetrabenazine may enhance the adverse/toxic effect of Valbenazine. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of valbenazine together with tetrabenazine is contraindicated.</p> \n<p><b>Discussion</b> Concurrent use of valbenazine and tetrabenazine is contraindicated.<sup>1</sup> The likely concern with concurrent use is an excessive or overlapping effect on neuronal monoamine neurotransmitter stores.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Xenazine (tetrabenazine) [prescribing information]. Deerfield, IL: Lundbeck; September 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11625":"<p><b>Title</b> Triazolam / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Triazolam. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid use of triazolam and strong CYP3A4 inhibitors. This combination is listed as a contraindication in triazolam prescribing information.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In several pharmacokinetic studies, the AUC of triazolam was significantly increased when combined with ketoconazole (12.7- to 22-fold),<sup>1,2</sup> itraconazole (3.48- to 26.1-fold),<sup>2,3</sup> ritonavir (19.4- to 22-fold),<sup>4,5</sup> nefazodone (2.9-fold),<sup>6</sup> and clarithromycin (4.25-fold).<sup>7</sup> In another study, nefazodone (200 mg daily) increased triazolam serum concentrations 60%.<sup>8</sup> <br><br>The triazolam prescribing information states that use with strong inhibitors of CYP3A4 is contraindicated and that they should not be taken with triazolam.<sup>9</sup> The prescribing information for numerous strong CYP3A4 inhibitors also list use with triazolam as a contraindication.<sup>10,11,12,13,14,15,16,17,18</sup><br><br>The mechanism of this interaction is likely CYP3A4 inhibition, resulting in reduced triazolam metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Varhe A, Olkkola K, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. <i>Clin Pharmacol Ther</i>. 1994;56(6 pt 1):601-607. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7995001\">[PubMed 7995001]</a></p>\n<p>2. Greenblatt DJ, Wright CE, von Moltke LL, et al. Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. <i>Clin Pharmacol Ther</i>. 1998;64(3):237-247. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9757147\">[PubMed 9757147]</a></p>\n<p>3. Neuvonen PJ, Varhe A, Olkkola KT. The effect of ingestion time interval on the interaction between itraconazole and triazolam. <i>Clin Pharmacol Ther</i>. 1996;60(3):326-331. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8841155\">[PubMed 8841155]</a></p>\n<p>4. Greeenblatt DJ, von Moltke LL, Harmatz JS, et al. Differential impairment of triazolam and zolpidem clearance by ritonavir. <i>J Acquir Immune Defic Syndr</i>. 2000;24(2):129-136. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10935688\">[PubMed 10935688]</a></p>\n<p>5. Culm-Merdek KE, von Moltke LL, Gan L, et al. Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir. <i>Clin Pharmacol Ther</i>. 2006;79(3):243-254. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16513448\">[PubMed 16513448]</a></p>\n<p>6. Barbhaiya RH, Shukla UA, Kroboth PD, Greene DS. Coadminstration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam. <i>J Clin Psychopharmacol</i>. 1995;15(5):320-326. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8830062\">[PubMed 8830062]</a></p>\n<p>7. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. <i>Clin Pharmacol Ther</i>. 1998;64(3):278-285. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9757151\">[PubMed 9757151]</a></p>\n<p>8. Kroboth PD, Folan MM, Lush RM, et al. Coadministration of nefazodone and benzodiazepines: I. Pharmacodynamics assessment. <i>J Clin Psychopharmacol</i>. 1995;15(5):306-319. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8830061\">[PubMed 8830061]</a></p>\n<p>9. Halcion (triazolam) [prescribing information]. New York, NY: Pharmacia and Upjohn Company LLC; September 2017.</p>\n<p>10. Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>11. Technivie (ombitasvir/paritaprevir/ritonavir) [prescribing information]. North Chicago, IL: AbbVie Inc; July 2015.</p>\n<p>12. Tybost (cobicistat) [prescribing information]. Foster City, CA: Gilead Sciences Inc; December 2014.</p>\n<p>13. Sporanox (itraconazole) [prescribing information]. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals Inc; April 2012.</p>\n<p>14. Nizoral (ketoconazole) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; July 2013.</p>\n<p>15. Reyataz (atazanavir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; April 2010.</p>\n<p>16. Prezista (darunavir) [prescribing information]. Raritan, NJ: Tibotec Therapeutics; April 2010.</p>\n<p>17. Kaletra (lopinavir and ritonavir) [prescribing information]. North Chicago, IL: Abbott Laboratories; April 2010.</p>\n<p>18. Norvir (ritonavir) [prescribing information]. North Chicago, IL: Abbott Laboratories; April 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11626":"<p><b>Title</b> ALPRAZolam / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of ALPRAZolam. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Consider using an alternative agent that is less likely to interact. If combined, monitor for increased therapeutic/toxic effects of alprazolam if a strong CYP3A4 inhibitor is initiated/dose increased, or decreased effects if a moderate CYP3A4 inhibitor is discontinued/dose decreased. Benzodiazepines less dependent on CYP3A-mediated metabolism (eg lorazepam, oxazepam, temazepam) are less likely to interact.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In several studies, the alprazolam AUC increased approximately 2- to 3-fold when coadministered with the strong CYP3A4 inhibitor ketoconazole.<sup>1,2,3,4</sup> The AUC of alprazolam increased approximately 2.5-fold with ritonavir,<sup>5</sup> 2.67-fold with itraconazole,<sup>6</sup> and 2.41-fold with nefazadone.<sup>7</sup> Pharmacodynamic effects were noted in the form of increased EEG beta amplitude for ketoconazole,<sup>2</sup> increased sedation and psychomotor performance impairment with ritonavir<sup>5</sup> and nefazadone,<sup>8</sup> and significantly depressed psychomotor function for itraconazole.<sup>6</sup><br><br>In contrast, in a cross-study of 9 patients with insomnia, nefazodone (200 mg per day for 1 week initiated after 1 week) much more mildly increased alprazolam (0.5 mg three times daily for 2 weeks) plasma levels by 34% though coadministration still caused more sedation than nefazodone alone.<sup>9</sup> <br><br>The mechanism of this interaction is likely CYP3A4 inhibition resulting in reduced alprazolam metabolism.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Xanax (alprazolam) [prescribing information]. New York, NY: Pfizer Inc; December 2016.</p>\n<p>2. Greenblatt DJ, Wright CE, von Moltke LL, et al. Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. <i>Clin Pharmacol Ther</i>. 1998;64(3):237-247. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9757147\">[PubMed 9757147]</a></p>\n<p>3. Boulenc X, Nicolas O, Hermabessiere S, et al. CYP3A4-based drug-drug interaction: CYP3A4 substrates' pharmacokinetic properties and ketoconazole dose regimen effect. <i>Eur J Drug Metab Pharmacokinet</i>. 2016;41(1):45-54. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25374256\">[PubMed 25374256]</a></p>\n<p>4. Schmider J, Brockmoller J, Arold G, Bauer S, Roots I. Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine. <i>Pharmacogenetics</i>. 1999;9(6):725-734. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10634135\">[PubMed 10634135]</a></p>\n<p>5. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Alprazolam-ritonavir interaction: implications for product labeling. <i>Clin Pharmacol Ther</i>. 2000;67(4):335-341. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10801241\">[PubMed 10801241]</a></p>\n<p>6. Yasui N, Kondo T, Otani K, et al. Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. <i>Psychopharmacology (Berl)</i>. 1998;139(3):269-273. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9784084\">[PubMed 9784084]</a></p>\n<p>7. Greene DS, Salazar DE, Dockens RC, Kroboth P, Barbhaiya RH. Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam. <i>J Clin Psychopharmacol</i>. 1995;15(6):399-408. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8748428\">[PubMed 8748428]</a></p>\n<p>8. Kroboth PD, Folan MM, Lush RM, et al. Coadministration of nefazodone and benzodiazepines: I. Pharmacodynamic assessment. <i>J Clin Psychopharmacol</i>. 1995;15(5):306-319. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8830061\">[PubMed 8830061]</a></p>\n<p>9. Rickels K, Schweizer E, Case WG, et al. Nefazodone in major depression: adjunctive benzodiazepine therapy and tolerability. <i>J Clin Psychopharmacol</i>. 1998;18(2):145-153. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9580369\">[PubMed 9580369]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11627":"<p><b>Title</b> Loop Diuretics / Xipamide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Xipamide may enhance the adverse/toxic effect of Loop Diuretics. Specifically, the risk of hypovolemia, electrolyte disturbances, and prerenal azotemia may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor fluid, electrolyte, and renal status closely in patients receiving xipamide and loop diuretics concomitantly.</p>\n<div>\n <p><b>Loop Diuretics Interacting Members</b> Bumetanide, Ethacrynic Acid, Furosemide, Torsemide</p>\n</div> \n<p><b>Discussion</b> A case series describes the development of severe hypovolemia, electrolyte disturbances, and/or prerenal azotemia in 6 elderly patients (ages 65-85 years) receiving xipamide (20-40 mg/day) in combination with furosemide (20-250 mg/day).<sup>1</sup> Severe hypokalemia and hyponatremia were the most common adverse reactions, with reported laboratory values as low as 1.4 mmol/L and 108 mmol/L, respectively. Findings consistent with prerenal azotemia developed in 5 patients, 4 of whom recovered completely after cessation of one or both diuretics. <br><br>Citing the potential for an increased risk of fluid and electrolyte disturbances, the xipamide product labeling cautions that adequate monitoring is required if xipamide and loop diuretics are used concomitantly.<sup>2</sup><br><br>The precise mechanism for this proposed interaction is unknown, but the additive effect of two potent diuretics working at different sites of the renal tubule may contribute.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sandhofer A, Kahler C, Heininger D, et al. Severe electrolyte disturbances and renal failure in elderly patients with combined diuretic therapy including xipamid. <i>Wien Klin Wochenschr</i>. 2002;114(21-22):938-942. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12528327\">[PubMed 12528327]</a></p>\n<p>2. Diurexan (xipamide) tablets [summary of product characteristics]. Bishop’s Stortford, United Kingdom: Meda Pharmaceuticals Ltd; December 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11628":"<p><b>Title</b> Abemaciclib / Ketoconazole (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ketoconazole (Systemic) may increase the serum concentration of Abemaciclib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of abemaciclib and ketoconazole.</p> \n<p><b>Discussion</b> According to the abemaciclib prescribing information, concomitant use of ketoconazole and abemaciclib is predicted to increase the abemaciclib AUC up to 16-fold.<sup>1</sup> Since this may lead to increased abemaciclib toxicities, use of ketoconazole and abemaciclib should be avoided.<sup>1</sup><br><br>The mechanism of this interaction has not been fully investigated, but ketoconazole-mediated inhibition of CYP3A4, an enzyme involved in abemaciclib metabolism, likely contributes.<sup>1</sup> Ketoconazole-mediated inhibition of P-glycoprotein and/or BCRP may also contribute.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Verzenio (abemaciclib) [prescribing information]. Indianapolis, IN: Lilly USA LLC; September 2017.</p>\n<p>2. Vermeer LM, Isringhausen CD, Ogilvie BW, Buckley DB. Evaluation of ketoconazole and its alternative clinical CYP3A4/5 inhibitors as inhibitors of drug transporters: the in vitro effects of ketoconazole, ritonavir, clarithromycin, and itraconazole on 13 clinically-relevant drug transporters. <i>Drug Metab Dispos</i>. 2016;44(3):453-459. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26668209\">[PubMed 26668209]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11629":"<p><b>Title</b> Abemaciclib / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Abemaciclib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> In patients taking abemaciclib at a dose of 200 mg twice daily or 150 mg twice daily, reduce the abemaciclib dose to 100 mg twice daily when combined with strong CYP3A4 inhibitors. In patients who have had a dose reduction to 100 mg twice daily due to adverse reactions, further reduce the abemaciclib dose to 50 mg twice daily when combined with strong CYP3A4 inhibitors. <br><br>If a patient taking abemaciclib discontinues a strong CYP3A4 inhibitor, increase the abemaciclib dose (after 3 to 5 half-lives of the inhibitor) to the dose that was used before starting the strong CYP3A4 inhibitor.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the abemaciclib prescribing information, clarithromycin (500 mg twice daily) coadministered with abemaciclib (50 mg single dose) increased the relative potency adjusted AUC of abemaciclib plus its active metabolites (M2, M18, and M20) by 1.7-fold in cancer patients.<sup>1</sup> Itraconazole is predicted to increase the relative potency adjusted AUC of abemaciclib plus its active metabolites by 2.2-fold.<sup>1</sup><br><br>Abemaciclib prescribing information states that in patients taking abemaciclib at a dose of 200 mg twice daily or 150 mg twice daily, the abemaciclib dose should be reduced to 100 mg twice daily when combined with strong CYP3A4 inhibitors.<sup>1</sup> In patients who have had a dose reduction to 100 mg twice daily due to adverse reactions, a further abemaciclib dose reduction to 50 mg twice daily is recommended when combined with strong CYP3A4 inhibitors.<sup>1</sup><br><br>The mechanism of this interaction is likely inhibition of CYP34, an enzyme responsible for abemaciclib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Verzenio (abemaciclib) [prescribing information]. Indianapolis, IN: Lilly USA LLC; September 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11630":"<p><b>Title</b> Abemaciclib / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Abemaciclib. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased abemaciclib toxicities if combined with moderate CYP3A4 inhibitors.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> According to the abemaciclib prescribing information, diltiazem and verapamil (moderate CYP3A inhibitors) are predicted to increase the relative potency adjusted AUC of abemaciclib plus its active metabolites (M2, M18, and M20) by 1.7-fold and 1.3-fold, respectively.<sup>1</sup><br><br>The mechanism of this interaction is likely due to inhibition of CYP3A4, an enzyme responsible for abemaciclib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Verzenio (abemaciclib) [prescribing information]. Indianapolis, IN: Lilly USA LLC; September 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11631":"<p><b>Title</b> Abemaciclib / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Abemaciclib. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of abemaciclib and strong CYP3A4 inducers.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the abemaciclib prescribing information, rifampin (600 mg daily) coadministered with abemaciclib (200 mg single dose) decreased the relative potency adjusted AUC of abemaciclib plus its active metabolites (M2, M18, and M20) by 67% in healthy subjects.<sup>1</sup><br><br>Abemaciclib prescribing information states that because use with strong CYP3A4 inducers may lead to decreased efficacy, concomitant use of abemaciclib and strong CYP3A4 inducers should be avoided.<br><br>The mechanism of this interaction is likely rifampin-mediated induction of CYP3A4, an enzyme responsible for abemaciclib metabolism.<sup>1</sup> Rifampin-mediated induction of P-glycoprotein may also contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Verzenio (abemaciclib) [prescribing information]. Indianapolis, IN: Lilly USA LLC; September 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11632":"<p><b>Title</b> MetFORMIN / Abemaciclib</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Abemaciclib may increase the serum concentration of MetFORMIN. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased metformin effects/toxicities if combined with abemaciclib.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the abemaciclib prescribing information, abemaciclib (400 mg single dose) increased the metformin (1,000 mg single dose) AUC and maximum serum concentration 37% and 22%, respectively.<sup>1</sup> Abemaciclib also reduced the renal clearance and renal secretion of metformin 45% and 62%, respectively.<sup>1</sup><br><br>The mechanism of this interaction is likely due to abemaciclib-mediated inhibition of OCT2, MATE1, and MATE-2K, transporters involved in the active tubular secretion of metformin.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Verzenio (abemaciclib) [prescribing information]. Indianapolis, IN: Lilly USA LLC; September 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11633":"<p><b>Title</b> Abemaciclib / Grapefruit Juice</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Grapefruit Juice may increase the serum concentration of Abemaciclib. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid consumption of grapefruit juice while taking abemaciclib.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the abemaciclib prescribing information, the strong CYP3A4 inhibitor clarithromycin (500 mg twice daily) coadministered with abemaciclib (50 mg single dose) increased the relative potency adjusted AUC of abemaciclib plus its active metabolites (M2, M18, and M20) by 1.7-fold in cancer patients.<sup>1</sup> Ketoconazole and itraconazole are predicted to increase the relative potency adjusted AUC of abemaciclib plus its active metabolites by 16-fold and 2.2-fold, respectively.<sup>1</sup> The moderate CYP3A4 inhibitors diltiazem and verapamil are predicted to increase the relative potency adjusted AUC of abemaciclib plus its active metabolites (M2, M18, and M20) by 1.7-fold and 1.3-fold, respectively.<sup>1</sup> <br><br>The abemaciclib prescribing information states that because inhibitors of CYP3A4 increase abemaciclib concentrations and may lead to increased toxicities, patients should avoid consuming grapefruit juice (generally considered a moderate CYP3A4 inhibitor) while taking abemaciclib.<sup>1</sup><br><br>The mechanism of this interaction is likely due to inhibition of CYP3A4, an enzyme responsible for abemaciclib metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Verzenio (abemaciclib) [prescribing information]. Indianapolis, IN: Lilly USA LLC; September 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11634":"<p><b>Title</b> Cefuroxime / Proton Pump Inhibitors</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Route</b>: This interaction only applies to orally administered cefuroxime axetil. This interaction does not apply when cefuroxime is administered via the intravenous or intramuscular routes.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Proton Pump Inhibitors may decrease the absorption of Cefuroxime. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of oral cefuroxime axetil and proton pump inhibitors.</p>\n<div>\n <p><b>Proton Pump Inhibitors Interacting Members</b> Dexlansoprazole, Esomeprazole, Lansoprazole, Omeprazole, Pantoprazole, RABEprazole, Revaprazan</p>\n</div> \n<p><b>Discussion</b> The concomitant use of cefuroxime and proton pump inhibitors has not been evaluated in a clinical study. However, in a clinical study of 6 healthy volunteers, the AUC of cefuroxime (given as a single dose of 1,000 mg cefuroxime axetil) was reduced by more than 60% when coadministered with a combination of ranitidine and sodium bicarbonate.<sup>1</sup><br><br>In contrast, in a pharmacokinetic study of 7 dialysis patients, aluminum hydroxide (1,000 mg single dose) administered prior to cefuroxime axetil (1,000 mg single dose) had no effect on the maximum serum concentration or AUC of cefuroxime.<sup>2</sup><br><br>The cefuroxime axetil prescribing information states that because drugs that reduce gastric acidity may reduce the bioavailability of cefuroxime, the concomitant use of cefuroxime axetil and proton pump inhibitors should be avoided.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sommers DK, van Wyk M, Moncrieff J, Schoeman HS. Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil. <i>Br J Clin Pharmacol</i>. 1984;18(4):535-539. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6091711\">[PubMed 6091711]</a></p>\n<p>2. Brink HS, Huisman RM, Geerlings W, de Jong PE. Phosphate binders do not reduce bioavailability of oral cefuroxime-axetil in patients on peritoneal dialysis treatment. <i>Adv Perit Dial</i>. 1994;10:179-182. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7999822\">[PubMed 7999822]</a></p>\n<p>3. Ceftin (cefuroxime axetil) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11635":"<p><b>Title</b> LamoTRIgine / Estrogen Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Estrogen Derivatives may decrease the serum concentration of LamoTRIgine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased lamotrigine concentrations and effects if combined with estrogen derivatives.</p>\n<div>\n <p><b>Estrogen Derivatives Interacting Members</b> Diethylstilbestrol, Estradiol (Systemic), Estradiol (Topical), Estriol (Systemic), Estriol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated B/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estrone, Estropipate, Ethinyl Estradiol, Mestranol, Polyestradiol, Tibolone</p>\n</div> \n<p><b>Discussion</b> The majority of data to support this interaction has been observed with ethinyl estradiol. Plasma lamotrigine concentrations were an average of 49% lower in 7 patients following the addition of an oral contraceptive.<sup>1</sup> Most of the patients experienced increased seizure frequency when the contraceptive was added and/or adverse effects from lamotrigine following contraceptive discontinuation. Similarly, the lamotrigine AUC was an average of 52% lower with concurrent ethinyl estradiol and levonorgestrel in 16 subjects.<sup>2</sup> Similar changes in the dose-adjusted lamotrigine concentration with estrogen-containing contraceptives has been reported in several other studies.<sup>3,4,5,6</sup><br><br>The effect of other estrogen derivatives (used for hormone replacement therapy) on lamotrigine concentrations has been evaluated in only one retrospective study.<sup>7</sup> Lamotrigine serum concentrations were on average 16% lower in 79 women taking hormone replacement therapy (estradiol or estriol) compared with lamotrigine concentrations in 158 matched controls not taking hormone replacement therapy.<sup>7</sup><br><br>Increases in lamotrigine clearance and evidence of increased formation of the lamotrigine N-2-glucuronide suggest that the most likely mechanism for this interaction is enhanced lamotrigine glucuronidation (possibly via UGT1A4) by estrogens.<sup>4,5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sabers A, Buchholt JM, Uldall P, Hansen EL. Lamotrigine plasma levels reduced by oral contraceptives. <i>Epilepsy Res</i>. 2001;47(1-2):151-154. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11673029\">[PubMed 11673029]</a></p>\n<p>2. Sidhu J, Job S, Singh S, Philipson R. The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. <i>Br J Clin Pharmacol</i>. 2006;61(2):191-199. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16433873\">[PubMed 16433873]</a></p>\n<p>3. Reimers A, Helde G, Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. <i>Epilepsia</i>. 2005;46(9):1414-1417. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16146436\">[PubMed 16146436]</a></p>\n<p>4. Ohman I, Luef G, Tomson T. Effects of pregnancy and contraception on lamotrigine disposition: new insights through analysis of lamotrigine metabolites. <i>Seizure</i>. 2008;17(2):199-202. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18201913\">[PubMed 18201913]</a></p>\n<p>5. Wegner I, Edelbroek PM, Bulk S, Lindhout D. Lamotrigine kinetics within the menstrual cycle, after menopause, and with oral contraceptives. <i>Neurology</i>. 2009;73(17):1388-1393. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19858461\">[PubMed 19858461]</a></p>\n<p>6. Christensen J, Petrenaite V, Atterman J, et al. Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. <i>Epilepsia</i>. 2007;48(3):484-489. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17346247\">[PubMed 17346247]</a></p>\n<p>7. Reimers A. Hormone replacement therapy with estrogens may reduce lamotrigine serum concentrations: A matched case-control study. <i>Epilepsia</i>. 2017;58(1):e6-e9. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27805259\">[PubMed 27805259]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11636":"<p><b>Title</b> Pitolisant / Tricyclic Antidepressants</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Tricyclic Antidepressants may diminish the therapeutic effect of Pitolisant. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for evidence of decreased pitolisant effects if used with a tricyclic antidepressant.</p>\n<div>\n <p><b>Tricyclic Antidepressants Interacting Members</b> Amitriptyline, Amoxapine, ClomiPRAMINE, Desipramine, Dosulepin, Doxepin (Systemic), Doxepin (Topical), Imipramine, Lofepramine, Melitracen [INT], Nortriptyline, Protriptyline, Trimipramine</p>\n</div> \n<p><b>Discussion</b> Pitolisant labeling cautions that concurrent use of a tri- or tetracyclic antidepressant with pitolisant may diminish pitolisant effects.<sup>1,2</sup> Pitolisant enhances the activity of brain histaminergic receptors by blocking histamine autoreceptors via its actions as a H3-receptor antagonist or inverse agonist. Conversely, tri- and tetracyclic antidepressants have strong antihistamine effects, possibly antagonizing the histamine-stimulating effects of pitolisant.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wakix (pitolisant) [UK summary of product characteristics]. Paris, France: Bioprojet Pharma; March 2017.</p>\n<p>2. Wakix (pitolisant) [EMA summary of product characteristics]. Paris, France: Bioprojet Pharma; March 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11637":"<p><b>Title</b> Pitolisant / Antihistamines</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Antihistamines may diminish the therapeutic effect of Pitolisant. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for evidence of decreased pitolisant effects if used with an antihistamine.</p>\n<div>\n <p><b>Antihistamines Interacting Members</b> Acrivastine, Bilastine, Brompheniramine, Buclizine, Carbinoxamine, Cetirizine (Systemic), Chlorpheniramine, Clemastine, Cyclizine, Cyproheptadine, Desloratadine, Dexbrompheniramine, Dexchlorpheniramine, DimenhyDRINATE, Dimethindene (Systemic), DiphenhydrAMINE (Systemic), DiphenhydrAMINE (Topical), Doxylamine, Ebastine, Emedastine (Systemic), Fexofenadine, HydrOXYzine, Ketotifen (Systemic), Levocetirizine, Loratadine, Meclizine, Mequitazine, Olopatadine (Systemic), Oxatomide, Oxomemazine, Pheniramine, Phenyltoloxamine, Pizotifen, Pyrilamine (Systemic), Rupatadine, Thonzylamine, Trimeprazine, Triprolidine</p>\n</div> \n<p><b>Discussion</b> Pitolisant labeling cautions that concurrent use of an antihistamine with pitolisant may diminish pitolisant effects.<sup>1,2</sup> Pitolisant enhances the activity of brain histaminergic receptors by blocking histamine autoreceptors via its actions as a H3-receptor antagonist or inverse agonist. Conversely, drugs with strong antihistamine effects may possibly antagonize the histamine-stimulating effects of pitolisant.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wakix (pitolisant) [UK summary of product characteristics]. Paris, France: Bioprojet Pharma; March 2017.</p>\n<p>2. Wakix (pitolisant) [EMA summary of product characteristics]. Paris, France: Bioprojet Pharma; March 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11638":"<p><b>Title</b> Estrogen Derivatives (Contraceptive) / Pitolisant</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Pitolisant may diminish the therapeutic effect of Estrogen Derivatives (Contraceptive). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The combination of hormonal contraceptives with pitolisant should be avoided, and an alternate means of contraception should be used. An effective means of contraception has to be used during pitolisant therapy and for at least 21 days after stopping pitolisant.</p>\n<div>\n <p><b>Estrogen Derivatives (Contraceptive) Interacting Members</b> Ethinyl Estradiol, Mestranol</p>\n</div> \n<p><b>Discussion</b> Pitolisant labeling says that a contraceptive must be used during pitolisant therapy and for at least 21 days after cessation of pitolisant in women of childbearing age.<sup>1,2</sup> It is also stated that pitolisant may decrease the effectiveness of hormonal contraceptives, meaning that an alternative form of contraception is required. Of note, no specific data or reports on this reaction are provided.<br><br>The mechanism by which pitolisant would decrease hormonal contraceptive effectiveness is not clear, but it may be due to possible CYP3A4 induction of pitolisant, which is an effect that was reportedly observed in in vitro studies.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Wakix (pitolisant) [UK summary of product characteristics]. Paris, France: Bioprojet Pharma; March 2017.</p>\n<p>2. Wakix (pitolisant) [EMA summary of product characteristics]. Paris, France: Bioprojet Pharma; March 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11639":"<p><b>Title</b> Progestins (Contraceptive) / Pitolisant</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Pitolisant may diminish the therapeutic effect of Progestins (Contraceptive). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The combination of hormonal contraceptives with pitolisant should be avoided, and an alternate means of contraception should be used. An effective means of contraception has to be used during pitolisant therapy and for at least 21 days after stopping pitolisant.</p>\n<div>\n <p><b>Progestins (Contraceptive) Interacting Members</b> Chlormadinone, Desogestrel, Dienogest, Drospirenone, Ethynodiol Diacetate, Etonogestrel, Gestodene, Levonorgestrel (IUD), Levonorgestrel (Systemic), Lynestrenol, MedroxyPROGESTERone, Norelgestromin, Norethindrone, Norgestimate, Norgestrel</p>\n</div> \n<p><b>Discussion</b> Pitolisant labeling says that a contraceptive must be used during pitolisant therapy and for at least 21 days after cessation of pitolisant in women of childbearing age.<sup>1,2</sup> It is also stated that pitolisant may decrease the effectiveness of hormonal contraceptives, meaning that an alternative form of contraception is required. Of note, no specific data or reports on this reaction are provided.<br><br>The mechanism by which pitolisant would decrease hormonal contraceptive effectiveness is not clear, but it may be due to possible CYP3A4 induction of pitolisant, which is an effect that was reportedly observed in in vitro studies.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Wakix (pitolisant) [UK summary of product characteristics]. Paris, France: Bioprojet Pharma; March 2017.</p>\n<p>2. Wakix (pitolisant) [EMA summary of product characteristics]. Paris, France: Bioprojet Pharma; March 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11640":"<p><b>Title</b> Pitolisant / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Pitolisant. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use caution with concurrent use of pitolisant with CYP3A4 inducers, and monitor closely for evidence of decreased pitolisant effects. Pitolisant dose increases may be necessary, and the need for a possible dose increase should be assessed a week after starting the CYP3A4 inducer.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> The pitolisant maximum serum concentration and AUC were decreased by 39% and 50%, respectively, with concurrent use of the strong CYP3A4 inducer rifampin, according to data reported in the pitolisant labeling.<sup>1,2</sup><br><br>The exact clinical significance of this apparent interaction is unknown, but co-administration of pitolisant with strong CYP3A4 inducers should be done with caution, and pitolisant dose adjustments may be necessary.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wakix (pitolisant) [UK summary of product characteristics]. Paris, France: Bioprojet Pharma; March 2017.</p>\n<p>2. Wakix (pitolisant) [EMA summary of product characteristics]. Paris, France: Bioprojet Pharma; March 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11641":"<p><b>Title</b> Pitolisant / St John's Wort</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> St John's Wort may decrease the serum concentration of Pitolisant. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use caution with concurrent use of pitolisant with CYP3A4 inducers such as St John's wort, and monitor closely for evidence of decreased pitolisant effects. Pitolisant dose increases may be necessary, and the need for a possible dose increase should be assessed a week after starting St John's wort.</p> \n<p><b>Discussion</b> Specific data with St. John's wort are not available, but the pitolisant labeling does warn of a potential interaction based on the CYP3A4 induction potential of St. John's wort. The pitolisant maximum serum concentration and AUC were decreased by 39% and 50%, respectively, with concurrent use of the strong CYP3A4 inducer rifampin, according to data reported in the pitolisant labeling.<sup>1,2</sup><br><br>The exact clinical significance of this apparent interaction is unknown, but co-administration of pitolisant with CYP3A4 inducers such as St. John's wort should be done with caution, and pitolisant dose adjustments may be necessary.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wakix (pitolisant) [UK summary of product characteristics]. Paris, France: Bioprojet Pharma; March 2017.</p>\n<p>2. Wakix (pitolisant) [EMA summary of product characteristics]. Paris, France: Bioprojet Pharma; March 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11642":"<p><b>Title</b> Pitolisant / CYP2D6 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP2D6 Inhibitors (Strong) may increase the serum concentration of Pitolisant. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Use caution with concurrent use of pitolisant with CYP2D6 inhibitors, and monitor closely for evidence of increased pitolisant effects. Pitolisant dose reductions may be necessary.</p>\n<div>\n <p><b>CYP2D6 Inhibitors (Strong) Interacting Members</b> FLUoxetine, PARoxetine, QuiNIDine, Tipranavir</p>\n</div> \n<p><b>Discussion</b> The pitolisant maximum serum concentration (Cmax) and AUC were increased by approximately 1.5- and 2-fold, respectively, with concurrent use of the strong CYP2D6 inhibitor paroxetine, according to data reported in the pitolisant labeling.<sup>1,2</sup> Additionally, the pitolisant Cmax and AUC were 2.7-fold and 3.2-fold higher, respectively, after a single pitolisant dose, and 2.1-fold and 2.4-fold higher, respectively, after 7 days of pitolisant therapy in CYP2D6 poor metabolizers compared with CYP2D6 extensive metabolizers.<sup>2</sup><br><br>The exact clinical significance of this apparent interaction is unknown, but co-administration of pitolisant with strong CYP2D6 inhibitors should be done with caution, and pitolisant dose adjustments may be necessary.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wakix (pitolisant) [UK summary of product characteristics]. Paris, France: Bioprojet Pharma; March 2017.</p>\n<p>2. Wakix (pitolisant) [EMA summary of product characteristics]. Paris, France: Bioprojet Pharma; November 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11643":"<p><b>Title</b> CYP3A4 Substrates (High risk with Inducers) / Pitolisant</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Pitolisant may decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.</p>\n<div>\n <p><b>CYP3A4 Substrates (High risk with Inducers) Interacting Members</b> Abemaciclib, Abiraterone Acetate, Acalabrutinib, Alfuzosin, ALPRAZolam, Amiodarone, AmLODIPine, Apixaban, Apremilast, Aprepitant, ARIPiprazole, ARIPiprazole Lauroxil, Armodafinil, Artemether, Asunaprevir, Atazanavir, AtorvaSTATin, Avanafil, Axitinib, Barnidipine, Bedaquiline, Benidipine, Benzhydrocodone, Benzphetamine, Bisoprolol, Blonanserin, Boceprevir, Bortezomib, Bosutinib, Brexpiprazole, Brigatinib, Bromperidol, Buprenorphine, BusPIRone, Cabazitaxel, Cabozantinib, Calcitriol (Systemic), CarBAMazepine, Cariprazine, Ceritinib, ChlordiazePOXIDE, Chloroquine, Cilnidipine, Cilostazol, Citalopram, Clarithromycin, ClonazePAM, Clorazepate, Cobicistat, Cobimetinib, Conivaptan, Copanlisib, Crizotinib, CycloSPORINE (Systemic), Cyproterone, Daclatasvir, Dantrolene, Dapsone (Systemic), Darifenacin, Darunavir, Dasabuvir, Dasatinib, Deflazacort, Delavirdine, Dexamethasone (Systemic), DiazePAM, Dienogest, Digitoxin, DilTIAZem, Disopyramide, DOCEtaxel, Doxazosin, DOXOrubicin (Conventional), DOXOrubicin (Liposomal), Dronedarone, Dydrogesterone, Ebastine, Efavirenz, Elbasvir, Eliglustat, Elvitegravir, Enzalutamide, Eplerenone, Erlotinib, Erythromycin (Systemic), Escitalopram, Estradiol (Systemic), Estradiol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated B/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estrone, Estropipate, Eszopiclone, Ethinyl Estradiol, Ethosuximide, Etizolam, Etoposide, Etoposide Phosphate, Etoricoxib, Etravirine, Everolimus, Exemestane, Felbamate, Felodipine, Fesoterodine, Flibanserin, Flurazepam, Fosamprenavir, Fosaprepitant, Gefitinib, Gemigliptin, Grazoprevir, GuanFACINE, Halofantrine, Haloperidol, HYDROcodone, HYDROXYprogesterone Caproate, Ibrutinib, Idelalisib, Imatinib, Indinavir, Irinotecan (Conventional), Irinotecan (Liposomal), Isavuconazonium Sulfate, Isosorbide Dinitrate, Isosorbide Mononitrate, Isradipine, Itraconazole, Ivabradine, Ivacaftor, Ixabepilone, Ixazomib, Ketoconazole (Systemic), Lacidipine, Lansoprazole, Lapatinib, Lercanidipine, Levonorgestrel (Systemic), Lidocaine (Systemic), Linagliptin, Lomitapide, Losartan, Lovastatin, Lumefantrine, Lurasidone, Lynestrenol, Macimorelin, Macitentan, Manidipine, Maraviroc, MedroxyPROGESTERone, Mefloquine, Mestranol, Methadone, Mianserin, Midazolam, Midostaurin, MiFEPRIStone, Mirodenafil, Mirtazapine, Modafinil, Naldemedine, Naloxegol, Nefazodone, Nelfinavir, Neratinib, Netupitant, Nevirapine, NiCARdipine, NIFEdipine, Nilotinib, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Norethindrone, Norgestrel, Olaparib, Olmutinib, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Ondansetron, Osimertinib, Ospemifene, OxyCODONE, PACLitaxel (Conventional), PACLitaxel (Protein Bound), Palbociclib, Panobinostat, PAZOPanib, Perampanel, Pimozide, Piperaquine, Pipotiazine, Praziquantel, Primaquine, Progesterone, QUEtiapine, QuiNIDine, QuiNINE, RABEprazole, Radotinib, Ranolazine, Regorafenib, Repaglinide, Ribociclib, Rifabutin, Rilpivirine, Riociguat, Ritonavir, Rivaroxaban, Roflumilast, Rolapitant, RomiDEPsin, Saquinavir, Sildenafil, Silodosin, Simeprevir, Simvastatin, Sirolimus, Solifenacin, Sonidegib, Stiripentol, SUNItinib, Suvorexant, Tacrolimus (Systemic), Tamoxifen, Tamsulosin, Tasimelteon, Telaprevir, Telithromycin, Temsirolimus, Teniposide, Tetracycline (Systemic), Tezacaftor, TiaGABine, Tibolone, Ticagrelor, Ticlopidine, Tipranavir, Tofacitinib, Tolterodine, Tolvaptan, Toremifene, Trabectedin, TraMADol, TraZODone, Triazolam, Trimethoprim, Trimipramine, Ulipristal, Valbenazine, Vandetanib, Velpatasvir, Vemurafenib, Venetoclax, Venlafaxine, Verapamil, Vilazodone, VinBLAStine, VinCRIStine, VinCRIStine (Liposomal), Vinflunine, Vortioxetine, Voxilaprevir, Zolpidem, Zonisamide, Zopiclone</p>\n</div> \n<p><b>Discussion</b> Specific data concerning this interaction are not available, but the pitolisant labeling recommends avoiding concurrent use of pitolisant with CYP3A4 substrates that have a narrow therapeutic index due to the potential for pitolisant to induce CYP3A4.<sup>1,2</sup> This possible CYP3A4 induction was shown in vitro, so the clinical relevance of any such effect is not certain.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Wakix (pitolisant) [UK summary of product characteristics]. Paris, France: Bioprojet Pharma; March 2017.</p>\n<p>2. Wakix (pitolisant) [EMA summary of product characteristics]. Paris, France: Bioprojet Pharma; March 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11656":"<p><b>Title</b> LamiVUDine / Sorbitol</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Sorbitol may decrease the serum concentration of LamiVUDine. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> When possible, avoid chronic coadministration of sorbitol-containing solutions with lamivudine, but if this combination cannot be avoided, monitor patients more closely for possible therapeutic failure associated with decreased lamivudine exposure.</p> \n<p><b>Discussion</b> The lamivudine AUC was reduced by an average of 14% to 44% with concurrent sorbitol-containing oral solutions in a study of 16 healthy volunteers who received a single dose of lamivudine oral solution (300 mg) with different doses of sorbitol.<sup>1,2,3</sup> This interaction was dose-dependent, with sorbitol doses of 3.2 g, 10.2 g, and 13.4 g associated with 14% to 20%, 32% to 39%, and 36% to 44% reductions in lamivudine AUC, respectively. The lamivudine maximum serum concentration was similarly reduced by 28% to 55% with increasing sorbitol doses.<br><br>The labeling for many lamivudine-containing products contain recommendations to avoid this combination when possible, <sup>1,2,3,4</sup> but there are some labels that do not yet contain this recommendation.<sup>5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Epivir-HBV (lamivudine) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; September 2017.</p>\n<p>2. Triumeq (dolutegravir, abacavir and lamivudine) [product monograph]. Laval, Quebec, Canada: ViiV Healthcare ULC; May 2017.</p>\n<p>3. Trizivir (zidovudine, abacavir and lamivudine) [product monograph]. Laval, Quebec, Canada: ViiV Healthcare ULC; May 2017.</p>\n<p>4. Symfi Lo (efavirenz, lamivudine and tenofovir disoproxil fumarate) [prescribing information]. Morgantown, WV: Mylan Specialty L.P.; February 2018.</p>\n<p>5. Triumeq (abacavir, dolutegravir, and lamivudine) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; March 2017.</p>\n<p>6. Trizivir (abacavir, lamivudine, and zidovudine) [prescribing information]. Research Triangle Park, NC: ViiV Healthcare; March 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11657":"<p><b>Title</b> Droxidopa / Ifenprodil</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ifenprodil may diminish the therapeutic effect of Droxidopa. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients for evidence of reduced response to droxidopa when used concomitantly with ifenprodil.</p> \n<p><b>Discussion</b> At least one of the product labels for ifenprodil cautions that the activity of droxidopa may be reduced when the agents are used concomitantly.<sup>1</sup> <br><br>The mechanism of this possible interaction is unknown; however, cerebral vasodilation caused by ifenprodil may counteract the vasoconstrictive effects of droxidopa, which is converted in vivo to norepinephrine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ferodil (ifenprodil) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrug Product.jsp?item_Seq=200302015. Accessed January 26, 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11658":"<p><b>Title</b> Monoamine Oxidase Inhibitors / Diphenoxylate</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Diphenoxylate may enhance the hypertensive effect of Monoamine Oxidase Inhibitors. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of diphenoxylate and monoamine oxidase inhibitors.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> The diphenoxylate/atropine prescribing information states that because the chemical structure of diphenoxylate hydrochloride is similar to that of meperidine hydrochloride, the concurrent use of diphenoxylate with monoamine oxidase (MAO) inhibitors may, in theory, precipitate a hypertensive crisis.<sup>1</sup> Diphenoxylate/atropine should be avoided in patients who take MAO inhibitors.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Lomotil (diphenoxylate/atropine) [prescribing information]. New York, NY: Pfizer Inc; October 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11659":"<p><b>Title</b> Pergolide / Macrolide Antibiotics</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Macrolide Antibiotics may enhance the adverse/toxic effect of Pergolide. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Macrolide Antibiotics Interacting Members</b> Azithromycin (Systemic), Clarithromycin, Erythromycin (Systemic), Fidaxomicin, Roxithromycin, Spiramycin, Telithromycin</p>\n</div> \n<p><b>Discussion</b> Pergolide prescribing information states that caution should be exercised with the concomitant use of pergolide and macrolide antibiotics.<sup>1</sup> There are no cases of this possible interaction published in the English language and a mechanism by which these agents may interact has not been identified or proposed.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Pergolide tablets [summary of product characteristics]. Castleford, West Yorkshire, United Kingdom: Norton Healthcare Limited; April 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11660":"<p><b>Title</b> Nalfurafine / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nalfurafine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increase nalfurafine effects/toxicities if combined with CYP3A4 inhibitors.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the nalfurafine product labeling, ketoconazole (400 mg) increased the nalfurafine (10 mcg) AUC and maximum serum concentration 61% and 50%, respectively.<sup>1</sup><br><br>Nalfurafine product labeling states that if nalfurafine is combined with CYP3A4 inhibitors, patients should be monitored closely for increased nalfurafine effects and toxicities.<sup>1</sup> Nalfurafine dose reductions or discontinuation may be required to reduce adverse effects.<sup>1</sup><br><br>The mechanism of this interaction is likely due to ketoconazole-mediated inhibition of CYP3A4, an enzyme responsible for nalfurafine metabolism.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ramitch (nalfurafine) capsule [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=201307707. Accessed May 2017.</p>\n<p>2. Ando A, Oshida K, Fukuyama S, Watanabe A, Hashimoto H, Miyamoto Y. Identification of human cytochrome P450 enzymes involved in the metabolism of a novel kappa-opioid receptor agonist, nalfurafine hydrochloride. <i>Biopharm Drug Dispos</i>. 2012;33(5):257-264. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22581509\">[PubMed 22581509]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11661":"<p><b>Title</b> Nalfurafine / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nalfurafine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increase nalfurafine effects/toxicities if combined with CYP3A4 inhibitors.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the nalfurafine product labeling, the strong CYP3A4 inhibitor ketoconazole (400 mg) increased the nalfurafine (10 mcg) AUC and maximum serum concentration 61% and 50%, respectively.<sup>1</sup><br><br>Nalfurafine product labeling states that if nalfurafine is combined with CYP3A4 inhibitors, patients should be monitored closely for increased nalfurafine effects and toxicities.<sup>1</sup> Nalfurafine dose reductions or discontinuation may be required to reduce adverse effects.<sup>1</sup><br><br>The mechanism of this interaction is likely due to ketoconazole-mediated inhibition of CYP3A4, an enzyme responsible for nalfurafine metabolism.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Ramitch (nalfurafine) capsule [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=201307707. Accessed May 2017.</p>\n<p>2. Ando A, Oshida K, Fukuyama S, Watanabe A, Hashimoto H, Miyamoto Y. Identification of human cytochrome P450 enzymes involved in the metabolism of a novel kappa-opioid receptor agonist, nalfurafine hydrochloride. <i>Biopharm Drug Dispos</i>. 2012;33(5):257-264. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22581509\">[PubMed 22581509]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11662":"<p><b>Title</b> Phosphodiesterase 5 Inhibitors / Alpha1-Blockers (Uroselective)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Alpha1-Blockers (Uroselective) may enhance the hypotensive effect of Phosphodiesterase 5 Inhibitors. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Use caution when coadministering alpha 1-blockers and phosphodiesterase 5 (PDE5) inhibitors. Ensure that the patient is stable on alpha 1-blocker before initiating a PDE5 inhibitor, and initiate the PDE5 inhibitor at the lowest recommended dose. If the patient has been using a PDE5 inhibitor, initiate the alpha 1-blocker at the lowest dose. Separating the doses of these agents may reduce the risk of adverse effects. Patients who are volume depleted and/or using antihypertensive treatment(s) may be at an even greater risk for adverse effects from such a combination. Uroselective agents such as tamsulosin, silodosin, or alfuzosin likely pose a lower risk than non-selective alpha 1-inhibitors such as doxazosin or terazosin. Monitor for hypotension in any patient receiving concomitant therapy with an alpha 1-blocker and a PDE5 inhibitor. According to tadalafil labeling, when tadalafil is used for benign prostatic hyperplasia (BPH), concurrent use of any alpha 1-blocker is not recommended, and any alpha 1-blocker should be discontinued at least 1 day prior to initiation. However, several published studies have reported that combined use of the specific alpha 1-inhibitor tamsulosin and tadalafil was well tolerated in patients with BPH or for expulsion of ureteric stones.</p>\n<div>\n <p><b>Phosphodiesterase 5 Inhibitors Interacting Members</b> Avanafil, Mirodenafil, Sildenafil, Tadalafil, Udenafil, Vardenafil</p>\n <p><b>Alpha1-Blockers (Uroselective) Interacting Members</b> Alfuzosin, Silodosin, Tamsulosin</p>\n</div> \n<p><b>Discussion</b> The concomitant administration of alpha 1-blockers (chronic, stable) and PDE5 inhibitors (single dose) generally results in mild-to-moderate reductions in blood pressure and symptoms of generally limited clinical concern (eg, dizziness, lightheadedness).<sup>1,2,3,4,5,6,7,8,9,10</sup> Symptomatic hypotension (with systolic BP &lt;85 mmHg) and significant (ie, more than 30 mmHg) blood pressure reductions have been reported in individual patients while receiving combination therapy (eg, sildenafil/doxazosin,<sup>2</sup> tadalafil/doxazosin,<sup>3,5</sup> vardenafil/terazosin or tamsulosin,<sup>1</sup> and avanafil/doxazosin or tamsulosin<sup>4</sup>). However, this seems to occur in a minority of patients, and some combinations appear more risky than others. In particular, combinations involving doxazosin or terazosin appear to pose a higher risk than combinations involving more specific agents such as tamsulosin or alfuzosin.<sup>1,3,4,5,6,11</sup> Several published studies of patients receiving both the specific alpha 1-inhibitor tamsulosin and tadalafil for treatment of BPH or for expulsion of ureteric stones have reported that the combination was well-tolerated with no significant risk of substantial hypotension-related adverse effects.<sup>12,13,14,15,16,17,18,19</sup><br><br>Higher doses of either drug are generally associated with a higher risk of adverse effects and greater blood pressure changes. For some combinations (eg, sildenafil/doxazosin,<sup>2</sup> vardenafil/terazosin<sup>1</sup>) separating the doses by 4 to 6 hours appears to minimize the effects. The adverse clinical effects noted during concomitant administration of alpha 1- blockers and PDE5 inhibitors is likely due to additive vasodilating effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Levitra (vardenafil) [prescribing information]. West Haven, CT: Bayer Pharmaceuticals Corporation; 2005.</p>\n<p>2. Viagra (sildenafil) [prescribing information]. New York, NY: Pfizer Pharmaceuticals; 2003.</p>\n<p>3. Cialis (tadalafil) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; October 2011.</p>\n<p>4. Stendra (avanafil) [prescribing information]. Mountain View, CA: Vivus, Inc; April 2012.</p>\n<p>5. Kloner RA, Jackson G, Emmick JT, et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. <i>J Urol</i>. 2004;172(5 pt 1):1935-1940. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15540759\">[PubMed 15540759]</a></p>\n<p>6. Auerbach SM, Gittelman M, Mazzu A, Cihon F, Sundaresan P, White WB. Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. <i>Urology</i>. 2004;64(5):998-1003. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15533493\">[PubMed 15533493]</a></p>\n<p>7. MacDiarmid SA, Hill LA, Volinn W, Hoel G. Lack of pharmacodynamic interaction of silodosin, a highly selective alpha1a-adrenoceptor antagonist, with the phosphodiesterase-5 inhibitors sildenafil and tadalafil in healthy men. <i>Urology</i>. 2010;75(3):520-525. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20080287\">[PubMed 20080287]</a></p>\n<p>8. Bang WJ, Oh CY, Yoo C, et al. Efficacy and safety of the simultaneous administration of mirodenafil and an alpha-blocker in men with BPH-LUTS: a multicenter open-label prospective study. <i>Int J Impot Res</i>. 2013;25(4):149-154. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23303333\">[PubMed 23303333]</a></p>\n<p>9. Lee JY, Cho SY, Oh CY, et al. Efficacy and safety of combination therapy with mirodenafil and alpha1-blocker for benign prostatic hyperplasia-induced lower urinary tract symptoms accompanied by erectile dysfunction: a multicenter, open-label, prospective study. <i>Int J Impot Res</i>. 2011;23(6):249-256. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21814227\">[PubMed 21814227]</a></p>\n<p>10. Chung BH, Lee JY, Lee SH, Yoo SJ, Lee SW, Oh CY. Safety and efficacy of the simultaneous administration of udenafil and an alpha-blocker in men with erectile dysfunction concomitant with BPH/LUTS. <i>Int J Impot Res</i>. 2009;21(2):122-128. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19194451\">[PubMed 19194451]</a></p>\n<p>11. Gu N, Kim J, Lim KS, et al. Assessment of the effect of mirodenafil on the hemodynamics of healthy male Korean volunteers administered tamsulosin: a randomized, double-blind, placebo-controlled, 2-period crossover study. <i>Clin Ther</i>. 2012;34(9):1929-1939. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22921287\">[PubMed 22921287]</a></p>\n<p>12. Kim SW, Park NC, Lee SW, et al. Efficacy and safety of a fixed-dose combination therapy of tamsulosin and tadalafil for patients with lower urinary tract symptoms and erectile dysfunction: results of a randomized, double-blinded, active-controlled trial. <i>J Sex Med</i>. 2017;14(8):1018-1027. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28760246\">[PubMed 28760246]</a></p>\n<p>13. Bai Y, Yang Y, Wang X, Tang Y, Han P, Wang J. Tadalafil facilitates the distal ureteral stone expulsion: a meta-analysis. <i>J Endourol</i>. 2017;31(6):557-563. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28384011\">[PubMed 28384011]</a></p>\n<p>14. Karami H, Hassanzadeh-Hadad A, Fallah-Karkan M. Comparing monotherapy with tadalafil or tamsulosin and their combination therapy in men with benign prostatic hyperplasia: a randomized clinical trial. <i>Urol J</i>. 2016;13(6):2920-2926. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27928815\">[PubMed 27928815]</a></p>\n<p>15. Jayant K, Agrawal R, Agrawal S. Tamsulosin versus tamsulosin plus tadalafil as medical expulsive therapy for lower ureteric stones: a randomized controlled trial. <i>Int J Urol</i>. 2014;21(10):1012-1015. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24894533\">[PubMed 24894533]</a></p>\n<p>16. Kumar S, Jayant K, Agrawal S, Singh SK. Comparative efficacy of tamsulosin versus tamsulosin with tadalafil in combination with prednisolone for the medical expulsive therapy of lower ureteric stones: a randomized trial. <i>Korean J Urol</i>. 2014;55(3):196-200. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24648875\">[PubMed 24648875]</a></p>\n<p>17. Singh DV, Mete UK, Mandal AK, Singh SK. A comparative randomized prospective study to evaluate efficacy and safety of combination of tamsulosin and tadalafil vs. tamsulosin or tadalafil alone in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. <i>J Sex Med</i>. 2014;11(1):187-196. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24165272\">[PubMed 24165272]</a></p>\n<p>18. Bechara A, Romano S, Casabe A, et al. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. <i>J Sex Med</i>. 2008;5(9):2170-2178. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18638006\">[PubMed 18638006]</a></p>\n<p>19. Guillaume M, Lonsdale F, Darstein C, Jimenez MC, Mitchell MI. Hemodynamic interaction between a daily dosed phosphodiesterase 5 inhibitor, tadalafil, and the alpha-adrenergic blockers, doxazosin and tamsulosin, in middle-aged healthy male subjects. <i>J Clin Pharmacol</i>. 2007;47(10):1303-1310. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17906163\">[PubMed 17906163]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11663":"<p><b>Title</b> Alpha1-Blockers (Nonselective) / Phosphodiesterase 5 Inhibitors</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: These classes of agents can be used together with caution for erectile dysfunction. If tadalafil is used for benign prostatic hyperplasia, discontinue any alpha 1-blocker at least 1 day prior to initiation.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Phosphodiesterase 5 Inhibitors may enhance the hypotensive effect of Alpha1-Blockers (Nonselective). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Use caution when coadministering alpha 1-blockers and phosphodiesterase 5 (PDE5) inhibitors. Ensure that the patient is stable on alpha 1-blocker before initiating a PDE5 inhibitor, and initiate the PDE5 inhibitor at the lowest recommended dose. If the patient has been using a PDE5 inhibitor, initiate the alpha 1-blocker at the lowest dose. Separating the doses of these agents may reduce the risk of adverse effects. Patients who are volume depleted and/or using additional antihypertensive treatment(s) may be at an even greater risk for adverse effects from such a combination. Tamsulosin or alfuzosin may pose a lower risk than doxazosin or terazosin. The effects of other alpha 1-blockers have not been well-studied. Monitor for hypotension in any patient receiving concomitant therapy with an alpha 1-blocker and a PDE5 inhibitor. If tadalafil is used for benign prostatic hyperplasia, concurrent use with an alpha 1-blocker is not recommended; discontinue any alpha 1-blocker at least 1 day prior to initiation.</p>\n<div>\n <p><b>Phosphodiesterase 5 Inhibitors Interacting Members</b> Avanafil, Mirodenafil, Sildenafil, Tadalafil, Udenafil, Vardenafil</p>\n <p><b>Alpha1-Blockers (Nonselective) Interacting Members</b> Doxazosin, Indoramin, Moxisylyte, Naftopidil, Nicergoline, Phenoxybenzamine, Phentolamine, Prazosin, Terazosin</p>\n</div> \n<p><b>Discussion</b> The concomitant administration of alpha 1-blockers (chronic, stable) and PDE5 inhibitors (single dose) generally results in mild-moderate reductions in blood pressure and symptoms of limited clinical concern (eg, dizziness, lightheadedness).<sup>1,2,3,4,5,6,7,8,9,10</sup> Symptomatic hypotension (with systolic BP &lt;85 mmHg) and significant (ie, more than 30 mmHg) blood pressure reductions have been reported in individual patients while receiving combination therapy (eg, sildenafil/doxazosin,<sup>2</sup> tadalafil/doxazosin,<sup>3,5</sup> vardenafil/terazosin or tamsulosin,<sup>1</sup> and avanafil/doxazosin or tamsulosin<sup>4</sup>). However, this seems to occur in a minority of patients, and some combinations appear more risky than others. In particular, combinations involving doxazosin or terazosin appear to pose a higher risk than combinations involving tamsulosin or alfuzosin.<sup>1,3,4,5,6,11</sup> Higher doses of either drug are generally associated with a higher risk of adverse effects and greater blood pressure changes. For some combinations (eg, sildenafil/doxazosin,<sup>2</sup> vardenafil/terazosin<sup>1</sup>) separating the doses by 4-6 hours appears to minimize the effects. The adverse clinical effects noted during concomitant administration of alpha 1- blockers and PDE5 inhibitors is likely due to additive vasodilating effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Levitra (vardenafil) [prescribing information]. West Haven, CT: Bayer Pharmaceuticals Corporation; 2005.</p>\n<p>2. Viagra (sildenafil) [prescribing information]. New York, NY: Pfizer Pharmaceuticals; 2003.</p>\n<p>3. Cialis (tadalafil) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; October 2011.</p>\n<p>4. Stendra (avanafil) [prescribing information]. Mountain View, CA: Vivus, Inc; April 2012.</p>\n<p>5. Kloner RA, Jackson G, Emmick JT, et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. <i>J Urol</i>. 2004;172(5 pt 1):1935-1940. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15540759\">[PubMed 15540759]</a></p>\n<p>6. Auerbach SM, Gittelman M, Mazzu A, Cihon F, Sundaresan P, White WB. Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. <i>Urology</i>. 2004;64(5):998-1003. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15533493\">[PubMed 15533493]</a></p>\n<p>7. MacDiarmid SA, Hill LA, Volinn W, Hoel G. Lack of pharmacodynamic interaction of silodosin, a highly selective alpha1a-adrenoceptor antagonist, with the phosphodiesterase-5 inhibitors sildenafil and tadalafil in healthy men. <i>Urology</i>. 2010;75(3):520-525. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20080287\">[PubMed 20080287]</a></p>\n<p>8. Bang WJ, Oh CY, Yoo C, et al. Efficacy and safety of the simultaneous administration of mirodenafil and an alpha-blocker in men with BPH-LUTS: a multicenter open-label prospective study. <i>Int J Impot Res</i>. 2013;25(4):149-154. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23303333\">[PubMed 23303333]</a></p>\n<p>9. Lee JY, Cho SY, Oh CY, et al. Efficacy and safety of combination therapy with mirodenafil and alpha1-blocker for benign prostatic hyperplasia-induced lower urinary tract symptoms accompanied by erectile dysfunction: a multicenter, open-label, prospective study. <i>Int J Impot Res</i>. 2011;23(6):249-256. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21814227\">[PubMed 21814227]</a></p>\n<p>10. Chung BH, Lee JY, Lee SH, Yoo SJ, Lee SW, Oh CY. Safety and efficacy of the simultaneous administration of udenafil and an alpha-blocker in men with erectile dysfunction concomitant with BPH/LUTS. <i>Int J Impot Res</i>. 2009;21(2):122-128. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19194451\">[PubMed 19194451]</a></p>\n<p>11. Gu N, Kim J, Lim KS, et al. Assessment of the effect of mirodenafil on the hemodynamics of healthy male Korean volunteers administered tamsulosin: a randomized, double-blind, placebo-controlled, 2-period crossover study. <i>Clin Ther</i>. 2012;34(9):1929-1939. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22921287\">[PubMed 22921287]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11664":"<p><b>Title</b> Dabigatran Etexilate / Fluconazole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fluconazole may enhance the anticoagulant effect of Dabigatran Etexilate. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for evidence of increased levels/effects (ie, bleeding) of dabigatran if used concomitantly with fluconazole. Consider using an alternative to fluconazole when possible.</p> \n<p><b>Discussion</b> According to a large retrospective cohort study of 91,330 Taiwanese patients with non-valvular atrial fibrillation who were treated with dabigatran (49.65% of participants) or another non-vitamin K antagonist oral anticoagulant (ie, rivaroxaban or apixaban), concurrent use of fluconazole was associated with a 2.35-fold increase in the incidence rate ratio for major bleeding, equivalent to an additional 138.5 major bleeding episodes per 1000 person-years as compared to an anticoagulant user who did not receive fluconazole.<sup>1</sup> Of note, several other combinations examined in this cohort study yielded findings contrary to what would be expected based on available pharmacokinetic interaction data or known pharmacology of the drugs in question. The precise clinical meaning of these findings is unclear.<br><br>The mechanism for this possible interaction is uncertain. Dabigatran is not appreciably metabolized, and although it is a substrate for P-glycoprotein (P-gp),<sup>2</sup> fluconazole has not been shown to be a clinically relevant inhibitor of P-gp, with some in vitro evidence even showing that it does not significantly inhibit P-gp.<sup>3,4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Chang SH, Chou IJ, Yeh YH, et al. Association between use of non-vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation. <i>JAMA</i>. 2017;318(13):1250-1259. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28973247\">[PubMed 28973247]</a></p>\n<p>2. Pradaxa (dabigatran etexilate). [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; November 2015.</p>\n<p>3. Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW. Interaction of common azole antifungals with P glycoprotein. <i>Antimicrob Agents Chemother</i>. 2002;46(1):160-165. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11751127\">[PubMed 11751127]</a></p>\n<p>4. Lempers VJ, van den Heuvel JJ, Russel FG, et al. Inhibitory potential of antifungal drugs on ATP-Binding Cassette transporters P-glycoprotein, MRP1 to MRP5, BCRP, and BSEP. <i>Antimicrob Agents Chemother</i>. 2016;60(6):3372-3379. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27001813\">[PubMed 27001813]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11665":"<p><b>Title</b> Alpha-/Beta-Agonists / Chloroprocaine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Chloroprocaine may enhance the hypertensive effect of Alpha-/Beta-Agonists. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor blood pressure closely if a vasopressor is used in a patient who has received chloroprocaine, monitoring specifically for evidence of a sustained or excessive blood pressure response.</p>\n<div>\n <p><b>Alpha-/Beta-Agonists Interacting Members</b> Amezinium, DOPamine, Ephedra, EPHEDrine (Nasal), EPHEDrine (Systemic), EPINEPHrine (Nasal), EPINEPHrine (Oral Inhalation), EPINEPHrine (Systemic), Isometheptene, Levonordefrin, Metaraminol, Norepinephrine, Pseudoephedrine</p>\n</div> \n<p><b>Discussion</b> The prescribing information for chloroprocaine warns that concomitant use of vasopressors used for the treatment of hypotension may increase the risk of cardiovascular adverse effects, including specifically prolonged hypertension and cerebrovascular accident.<sup>1,2</sup><br><br>The specific mechanism for this potential interaction is not specified.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Clorotekal (chloroprocaine) [prescribing information]. Mendrisio, Switzerland: Sintetica SA; September 2017.</p>\n<p>2. Nesacaine. (chloroprocaine) [prescribing information]. Schaumburg, IL: APP Pharmaceuticals, LLC; February 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11666":"<p><b>Title</b> Ergot Derivatives / Chloroprocaine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Chloroprocaine may enhance the hypertensive effect of Ergot Derivatives. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor blood pressure closely if an ergot derivative is used in a patient who has received chloroprocaine, monitoring specifically for evidence of a sustained or excessive blood pressure response.</p>\n<div>\n <p><b>Ergot Derivatives Interacting Members</b> Bromocriptine, Cabergoline, Dihydroergotamine, Ergoloid Mesylates, Ergonovine, Ergotamine, Methylergonovine, Nicergoline, Pergolide</p>\n</div> \n<p><b>Discussion</b> Several ergot derivatives act as peripheral vasoconstrictors via unknown mechanisms, and are associated with increases in blood pressure independent of concomitant use of other vasoconstrictors.<sup>1,2,3,4,5</sup> Prescribing information for chloroprocaine warns that concomitant ergot-type oxytocic drugs may increase the risk of cardiovascular adverse effects, including prolonged hypertension and cerebrovascular accident.<sup>6,7</sup><br><br>The specific mechanism for this potential interaction is not specified.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ergonovine [product monograph]. Toronto, ON: Alveda Pharmaceuticals Inc., March 2009.</p>\n<p>2. DHE 45 (dihydroergotamine) [prescribing information]. Costa Mesa, CA: Valeant Pharmaceuticals North America, July 2002.</p>\n<p>3. Parlodel (bromocriptine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, January 2012.</p>\n<p>4. Cafergot (ergotamine/caffeine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 3/2006.</p>\n<p>5. Chan KY, Vermeersch S, de Hoon J, et al. Potential mechanisms of prospective antimigraine drugs: a focus on vascular (side) effects. <i>Pharmacol Ther</i>. 2011;129(3):332-351. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21130807\">[PubMed 21130807]</a></p>\n<p>6. Clorotekal (chloroprocaine) [prescribing information]. Mendrisio, Switzerland: Sintetica SA; September 2017.</p>\n<p>7. Nesacaine. (chloroprocaine) [prescribing information]. Schaumburg, IL: APP Pharmaceuticals, LLC; February 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11667":"<p><b>Title</b> Phenylephrine (Systemic) / Chloroprocaine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Chloroprocaine may enhance the hypertensive effect of Phenylephrine (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor blood pressure closely if a vasopressor is used in a patient who has received chloroprocaine, monitoring specifically for evidence of a sustained or excessive blood pressure response.</p> \n<p><b>Discussion</b> The prescribing information for chloroprocaine warns that concomitant use of vasopressors used for the treatment of hypotension may increase the risk of cardiovascular adverse effects, including specifically prolonged hypertension and cerebrovascular accident.<sup>1,2</sup><br><br>The specific mechanism for this potential interaction is not specified.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Clorotekal (chloroprocaine) [prescribing information]. Mendrisio, Switzerland: Sintetica SA; September 2017.</p>\n<p>2. Nesacaine. (chloroprocaine) [prescribing information]. Schaumburg, IL: APP Pharmaceuticals, LLC; February 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11668":"<p><b>Title</b> Sulfonamide Antibiotics / Chloroprocaine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Chloroprocaine may diminish the therapeutic effect of Sulfonamide Antibiotics. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concurrent use of chloroprocaine and systemic sulfonamide-based antimicrobials whenever possible.</p>\n<div>\n <p><b>Sulfonamide Antibiotics Interacting Members</b> SulfADIAZINE, Sulfadoxine, Sulfamethoxazole, SulfiSOXAZOLE</p>\n</div> \n<p><b>Discussion</b> Very limited information, primarily from studies published in the 1940s, documents possible clinical antagonism of sulfonamide antimicrobial activity by procaine/local anesthetics.<sup>1,2,3,4,5,6</sup> However, it is known that plasma, and likely cerebrospinal cholinesterases, readily hydrolyze chloroprocaine to para-aminobenzoic acid (PABA). Given the known mechanism of sulfonamide antimicrobial activity (ie, competition with PABA for bacterial dihydropteroate synthase), it is plausible that sufficient amounts of chloroprocaine exposure could reduce the therapeutic actions of sulfonamide-based antibiotics. The circumstances under which this might occur, particularly given intrathecal administration of chloroprocaine, is unknown and may only be a concern with treatment of CNS infections. The chloroprocaine labeling discourages the concomitant use of chloroprocaine with sulfonamide drugs.<sup>7,8</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Peterson OL, Finland M. Sulfonamide inhibiting action of procaine. <i>Am J Med Sci</i>. 1944;207:166-75.</p>\n<p>2. Boroff DA, Cooper A, Bullowa JGM. Inhibition of sulfapyridine by procaine in chest fluids after procaine anesthesia. <i>Proc Soc Exp Biol Med</i>. 1941;47:182-183.</p>\n<p>3. Casten D, Fried JJ, Hallman FA. Inhibitory effect of procaine on the bacteriostatic activity of sulfathiazole. <i>Surg Gynecol Obstet</i>. 1943;76:726-728.</p>\n<p>4. Powell HM, Krahl ME, Clowes GHA. Inhibition of chemotherapeutic action of sulfapyridine by local anesthetics. <i>J Indiana State Med Assoc</i>. 1942;35:62-63.</p>\n<p>5. Walker BS, Derow MA. The antagonism of local anesthetics against the sulfonamides. <i>Am J Med Sci</i>. 1945;210:585-588.</p>\n<p>6. Pfeiffer CC, Grant CW. The procaine-sulfonamide antagonism: an evaluation of local anesthetics for use with sulfonamide therapy. <i>Anesthesiology</i>. 1944;5:605-614.</p>\n<p>7. Clorotekal (chloroprocaine) [prescribing information]. Mendrisio, Switzerland: Sintetica SA; September 2017.</p>\n<p>8. Nesacaine. (chloroprocaine) [prescribing information]. Schaumburg, IL: APP Pharmaceuticals, LLC; February 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11679":"<p><b>Title</b> Bradycardia-Causing Agents / Terlipressin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Terlipressin may enhance the bradycardic effect of Bradycardia-Causing Agents. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for enhanced bradycardic effects if terlipressin is combined with other bradycardia-causing agents.</p>\n<div>\n <p><b>Bradycardia-Causing Agents Interacting Members</b> Acebutolol, Ajmaline, Alectinib, Amiodarone, Arotinolol, Atenolol, Beractant, Betaxolol (Systemic), Bisoprolol, Bovine Lipid Extract Surfactant, Bovine Lung Extract, Brigatinib, Calfactant, Carteolol (Ophthalmic), Carvedilol, Celiprolol, Ceritinib, CloNIDine, Crizotinib, Dexmedetomidine, Digitoxin, Digoxin, DilTIAZem, Donepezil, Dronedarone, Esmolol, Fingolimod, Galantamine, Guanethidine, GuanFACINE, Ivabradine, Labetalol, Lanreotide, Levobunolol, Lofexidine, Lucinactant, Methyldopa, Metipranolol, Metoprolol, Moxonidine, Nadolol, Nebivolol, Octreotide, Oxprenolol, Pasireotide, Penbutolol, Pilsicainide, Pindolol, Poractant Alfa, Propafenone, Propranolol, Rilmenidine, Rivastigmine, Sotalol, SUFentanil, Timolol (Ophthalmic), Timolol (Systemic), TiZANidine, Verapamil</p>\n</div> \n<p><b>Discussion</b> The prescribing information for terlipressin cautions that terlipressin use may increase the bradycardic effects of other bradycardia-causing agents.<sup>1</sup> According to the summary of product characteristics, the incidence of bradycardia caused by terlipressin is between 1% and 10%; however, higher incidences have been reported in literature.<sup>2</sup> Terlipressin use causes an increase in systemic vascular resistance, which may result in a reflexive reduction in heart rate through the vagus nerve.<sup>1</sup><br><br>The mechanism of this proposed interaction is due to the additive effects of bradycardia-causing agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Variquel (terlipressin) injection [summary of product characteristics]. Wiltshire, United Kingdom: Alliance Pharmaceuticals Limited; August 2016.</p>\n<p>2. Reddy MS, Kaliamoorthy I, Rajakumar A, et al. Double-blind randomized controlled trial of the routine perioperative use of terlipressin in adult living donor liver transplantation. <i>Liver Transpl</i>. 2017;23(8):1007-1014. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28294557\">[PubMed 28294557]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11680":"<p><b>Title</b> PEMEtrexed / Ibuprofen</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Renal Function</b>: The severity of this potential interaction is likely greater in patients with impaired renal function.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ibuprofen may increase the serum concentration of PEMEtrexed. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> In any patient receiving pemetrexed and ibuprofen, monitor for increased pemetrexed toxicity (eg, myelosuppression, renal toxicity, gastrointestinal toxicity). <br><br>In patients with mild to moderate renal impairment (estimated creatinine clearance 45 to 79 mL/min) avoid ibuprofen for 2 days before, the day of, and 2 days following the administration of pemetrexed.<br><br>Alternative nonsteroidal anti-inflammatory drugs (NSAIDs) not expected to interact with pemetrexed include naproxen, diclofenac, and celecoxib.</p> \n<p><b>Discussion</b> The AUC of pemetrexed (500 mg/m<sup>2</sup> IV) was increased 20% in 27 patients (all of whom had a creatinine clearance [CrCL] greater than 60 mL/min; 3 of whom had a CrCL 60 to 80 mL/min) when administered following a 2-day regimen of ibuprofen (400 mg every 6 hours).<sup>1,2</sup> Mean maximum serum concentration of pemetrexed increased 15%, and pemetrexed clearance decreased an average of 16%.<sup>1</sup><br><br>Pemetrexed prescribing information states that ibuprofen can interfere with the renal elimination of pemetrexed, resulting in drug toxicity (eg, myelosuppression, nephrotoxicity, gastrointestinal toxicity), particularly in patients with impaired renal function.<sup>2</sup> In pemetrexed-treated patients with a CrCL of 45 to 79 mL/min, ibuprofen should be avoided for 2 days before, the day of, and 2 days following the administration of pemetrexed.<sup>2</sup><br><br>The mechanism of this interaction is likely due to ibuprofen-mediated inhibition of OAT3, a renal transporter responsible for pemetrexed elimination.<sup>1,2</sup> Other NSAIDs that are not expected to interact with pemetrexed include naproxen, diclofenac, and celecoxib.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sweeney CJ, Takimoto CH, Latz JE, et al. Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or ibuprofen in patients with advanced cancer. <i>Clin Cancer Res</i>. 2006;12(2):536-542. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16428497\">[PubMed 16428497]</a></p>\n<p>2. Alimta (pemetrexed) [prescribing information]. Indianapolis, IN: Lilly USA LLC; October 2017. </p>\n<p>3. Posada MM, Bacon JA, Schneck KB, et al. Prediction of renal transporter mediated drug-drug interactions for pemetrexed using physiologically based pharmacokinetic modeling. <i>Drug Metab Dispos</i>. 2015;43(3):325-334. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25504564\">[PubMed 25504564]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11681":"<p><b>Title</b> PrednisoLONE (Topical) / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of PrednisoLONE (Topical). <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> No studies have been conducted between strong CYP3A4 inhibitors and topical prednisolone. However, oral prednisolone/prednisone has been evaluated with numerous strong CYP3A4 inhibitors. <br><br>In a study of 4 healthy volunteers, administration of ketoconazole (200 mg daily for 6 days) resulted in no significant changes in the pharmacokinetics of prednisolone (the measured active metabolite) when administered with 20 mg oral prednisone.<sup>1</sup> Administration of intravenous prednisolone (20 mg single dose) following treatment with ketoconazole (200 mg daily for 6 days) also resulted in no change to prednisolone pharmacokinetic parameters in 6 healthy participants.<sup>2</sup> Another study of 14 healthy volunteers reported no change in prednisolone pharmacokinetics with the coadministration of prednisone (60 mg single dose) after itraconazole treatment (400 mg on day 1, 200 mg daily on days 2 through 4).<sup>3</sup> The absence of effect on prednisolone pharmacokinetics has also been reported with troleandomycin,<sup>4</sup> clarithromycin,<sup>5</sup> and grapefruit juice.<sup>6</sup><br><br>In contrast, in a study of 10 healthy subjects, administration of ritonavir (200 mg twice daily x 14.5 days) significantly increased prednisolone AUC following single 20 mg prednisone doses given on day 4 (37% increase) and day 14 (28% increase).<sup>7</sup> The AUC of prednisolone increased approximately 21%, 24%, and 47%, when prednisone or prednisolone was combined with diltiazem, itraconazole, and ketoconazole, respectively.<sup>8,9,10</sup> One brief letter describes the development of mania in a patient treated with prednisone 40 mg and clarithromycin 1000 mg daily.<sup>11</sup> The authors presume the reaction is a result of increased prednisone concentrations due to decreased metabolism caused by clarithromycin, though neurotoxicity has been reported as an adverse reaction to clarithromycin.<sup>12</sup><br><br>Topical prednisolone product labeling states that the combination of topical prednisolone and strong CYP3A4 inhibitors should be avoided unless the benefit outweighs the increased risk of<br>systemic corticosteroid side-effects.<sup>13,14</sup> Patients should be monitored for systemic corticosteroid side-effects.<sup>13,14</sup><br><br>The mechanism of this potential interaction is likely CYP3A4 inhibition resulting in reduced prednisolone metabolism. The conflicting results from various pharmacokinetic studies likely reflect the minor reliance of prednisolone on CYP3A4 for metabolic elimination and the strength of the CYP3A4 inhibitor. The magnitude of the interaction between strong CYP3A4 inhibitors and prednisolone is markedly less than with methylprednisolone or dexamethasone, steroids that rely heavily on CYP3A4 for elimination. Additionally, because topical prednisolone is expected to have significantly lower systemic concentrations than orally administered prednisolone, the risk of a clinically significant drug interaction is likely even further reduced.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ludwig EA, Slaughter RL, Savliwala M, Brass C, Jusko WJ. Steroid-specific effects of ketoconazole on corticosteroid disposition: unaltered prednisolone elimination. <i>DICP</i>. 1989;23(11):858-861. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2596127\">[PubMed 2596127]</a></p>\n<p>2. Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ. Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. <i>Clin Pharmacol Ther</i>. 1991;49(5):558-570. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1827622\">[PubMed 1827622]</a></p>\n<p>3. Lebrun-Vignes B, Archer VC, Diquet B, et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. <i>Br J Clin Pharmacol</i>. 2001;51(5):443-450. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11422002\">[PubMed 11422002]</a></p>\n<p>4. Szefler SJ, Ellis EF, Brenner M, et al. Steroid-specific and anticonvulsant interaction aspects of troleandomycin-steroid therapy. <i>J Allergy Clin Immunol</i>. 1982;69(5):455-460. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6978898\">[PubMed 6978898]</a></p>\n<p>5. Fost DA, Leung DY, Martin RJ, Brown EE, Szefler SJ, Spahn JD. Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy. <i>J Allergy Clin Immunol</i>. 1999;103(6):1031-1035. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10359882\">[PubMed 10359882]</a></p>\n<p>6. Hollander AA, van Rooij J, Lentjes GW, et al. The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients. <i>Clin Pharmacol Ther</i>. 1995;57(3):318-324. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7697949\">[PubMed 7697949]</a></p>\n<p>7. Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J. Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers. <i>J Acquir Immune Defic Syndr</i>. 2005;40(5):573-580. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16284534\">[PubMed 16284534]</a></p>\n<p>8. Imani S, Jusko W, Steiner R. Diltiazem retards the metabolism of oral prednisone with effects on T-cell markers. <i>Pediatr Transplant</i>. 1999;3(2):126-130. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10389134\">[PubMed 10389134]</a></p>\n<p>9. Varis T, Kivisto KT, Neuvonen PJ. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone. <i>Eur J Clin Pharmacol</i>. 2000;56(1):57-60. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10853878\">[PubMed 10853878]</a></p>\n<p>10. Zurcher RM, Frey BM, Frey FJ. Impact of ketoconazole on the metabolism of prednisolone. <i>Clin Pharmacol Ther</i>. 1999;45(4):366-372. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2639662\">[PubMed 2639662]</a></p>\n<p>11. Finkenbine R, Gill HS. Case of mania due to prednisone-clarithromycin interaction. <i>Can J Psychiatry</i>. 1997;42(7):778. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9307841\">[PubMed 9307841]</a></p>\n<p>12. Bandettini di Poggio M, Anfosso S, Audenino D, Primavera A. Clarithromycin-induced neurotoxicity in adults. <i>J Clin Neurosci</i>. 2011;18(3):313-318. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21269833\">[PubMed 21269833]</a></p>\n<p>13. Scheriproct (prednisolone and dibucaine) [summary of product characteristics]. Pymble NSW, Australia: Bayer Australia Ltd; October 2017.</p>\n<p>14. Predsol (prednisolone) retention enema [summary of product characteristics]. Jordbro, Sweden: RPH Pharmaceuticals AB; October 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11682":"<p><b>Title</b> Alcohol (Ethyl) / Cefoperazone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cefoperazone may enhance the adverse/toxic effect of Alcohol (Ethyl). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for signs and symptoms of a disulfiram-like reaction (eg, flushing, sweating, headache, tachycardia) if alcohol is ingested within 72 hours of cefoperazone administration.</p> \n<p><b>Discussion</b> A number of case reports describe the development of signs and symptoms consistent with a disulfiram-like reaction during coadministration of alcohol and various cephalosporins, including cefoperazone, cefamandole, cefotetan and moxalactam.<sup>1,2,3,4,5,6,7</sup> Facial flushing is the most common reaction, with or without nausea or vomiting. More severe reactions, including blood pressure changes requiring fluid and/or medication treatment, have been reported. The common link between these cephalosporins is the presence of a methyltetrazolethiol (MTT) sidechain in the chemical structure of the drug. Cephalosporins lacking this sidechain do not appear to be associated with this interaction. A mechanism for this interaction is unclear. It seems possible that the drugs inhibit acetaldehyde dehydrogenase, thus inhibiting the metabolism of acetaldehyde (the primary metabolite of alcohol). However, a study in normal subjects demonstrated no effects of cefotetan on the pharmacokinetics of either alcohol or acetaldehyde.<sup>7</sup><br><br>The prescribing information for cefoperazone states that disulfiram-like reactions have occurred when alcohol (beer, wine) was ingested within 72 hours of cefoperazone administration.<sup>8</sup> Cefoperazone contains an MTT sidechain in its chemical structure. Caution is warranted.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Neu HC, Prince AS. Interaction between moxalactam and alcohol. <i>Lancet</i>. 1980;1(8183):1422. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6104213\">[PubMed 6104213]</a></p>\n<p>2. Brown KR, Guglielmo BJ, Pons VG, et al. Theophylline elixir, moxalactam, and a disulfiram reaction. <i>Ann Intern Med</i>. 1982;97(4):621-622. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6214982\">[PubMed 6214982]</a></p>\n<p>3. Elenbaas RM, Ryan JL, Robinson WA, et al. On the disulfiram-like activity of moxalactam. <i>Clin Pharmacol Ther</i>. 1982;32(3):347-355. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6213349\">[PubMed 6213349]</a></p>\n<p>4. Portier H, Chalopin JM, Freysz M, et al. Interaction between cephalosporins and alcohol. <i>Lancet</i>. 1980;2(8188):263. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6105424\">[PubMed 6105424]</a></p>\n<p>5. Drummer S, Hauser WE Jr, Remington JS. Antabuse-like effect of beta-lactam antibiotics. <i>N Engl J Med</i>. 1980;303(24):1417-1418. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7432393\">[PubMed 7432393]</a></p>\n<p>6. Foster TS, Raehl CL, Wilson HD. Disulfiram-like reaction associated with a parenteral cephalosporin. <i>Am J Hosp Pharm</i>. 1980;37(6):858-859. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6446854\">[PubMed 6446854]</a></p>\n<p>7. Kline SS, Mauro VF, Forney RB Jr, et al. Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia. <i>Antimicrob Agents Chemother</i>. 1987;31(9):1328-1331. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3479045\">[PubMed 3479045]</a></p>\n<p>8. Cefobid (cefoperazone) injection [SG prescribing information]. New York, New York: Roerig; March 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11683":"<p><b>Title</b> Isoniazid / Aluminum Hydroxide</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction likely only applies to aluminum hydroxide gel.</p></li>\n <li><p><b>Route</b>: This interaction only applies to orally administered isoniazid.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Aluminum Hydroxide may decrease the absorption of Isoniazid. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In clinical trials of healthy subjects given both liquid and tablet antacids containing aluminum hydroxide and magnesium hydroxide with single doses of isoniazid, no changes in isoniazid peak serum levels, time of absorption, or AUC were observed.<sup>1,2</sup> One conflicting study in patients with active tuberculosis taking isoniazid demonstrated a 20% to 30% decrease in serum isoniazid levels after taking large quantities of a gel based aluminum hydroxide antacid.<sup>3</sup> Those taking magaldrate showed negligible decreases in isoniazid concentrations.<sup>3</sup> <br><br>An animal arm of the study theorized the gel formulation caused delayed gastric emptying.<sup>3</sup> A clinical trial of histamine 2 receptor antagonists indicated that pH changes were not responsible for decreased isoniazid concentrations.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Peloquin CA, Namdar R, Dodge AA, Nix DE. Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. <i>Int J Tuberc Lung Dis</i>. 1999;3(8):703-710. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10460103\">[PubMed 10460103]</a></p>\n<p>2. Gallicano K, Sahai J, Zaror-Behrens G, Pakuts A. Effects of antacids in didanosine tablet on bioavailability of isoniazid. <i>Antimicrob Agents Chemother</i>. 1994;38(4):894-897. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8031068\">[PubMed 8031068]</a></p>\n<p>3. Hurwitz A, Schlozman DL. Effects of antacids on gastrointestinal absorption of isoniazid in rats and man. <i>Am Rev Respir Dis</i>. 1974;109(1):41-47. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4588090\">[PubMed 4588090]</a></p>\n<p>4. Paulsen O, Hoglund P, Nilsson LG, Gredeby H. No interaction between H2 blockers and isoniazid. <i>Eur J Respir Dis</i>. 1986;68(4):286-290. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2874048\">[PubMed 2874048]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11684":"<p><b>Title</b> Fluconazole / HydroCHLOROthiazide</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> HydroCHLOROthiazide may increase the serum concentration of Fluconazole. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 13 healthy volunteers described in the fluconazole prescribing information, coadministration of hydrochlorothiazide (50 mg daily) and fluconazole (100 mg daily) for 10 days increased the fluconazole AUC and maximum serum concentration 45% and 43%, respectively.<sup>1</sup> The renal clearance of fluconazole was reduced 30%.<sup>1</sup><br><br>Fluconazole prescribing information states that although coadministration with hydrochlorothiazide may increase fluconazole concentrations, the magnitude of this interaction does not necessitate a fluconazole dose adjustment.<sup>1</sup><br><br>The mechanism of this interaction has not been fully investigated, but hydrochlorothiazide may reduce the renal elimination of fluconazole.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Diflucan (fluconazole) [prescribing information]. New York, NY: Pfizer Inc; September 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11685":"<p><b>Title</b> Terfenadine / Fluconazole</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fluconazole may enhance the QTc-prolonging effect of Terfenadine. Fluconazole may increase the serum concentration of Terfenadine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of fluconazole at doses of 400 mg/day or greater and terfenadine. This combination is listed as a contraindication in the fluconazole prescribing information. If lower doses of fluconazole and terfenadine are combined, monitor patients for QT-prolongation.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 6 healthy volunteers, coadministration of fluconazole (200 mg daily) and terfenadine (60 mg twice daily) for 7 days had no effect on the pharmacokinetics of the parent drug terfenadine, but did increase the AUC of the terfenadine acid metabolite 34%.<sup>1,2</sup> There was no change in the QTc interval with the combination compared with terfenadine alone.<sup>1,2</sup> In another study described in the fluconazole prescribing information, fluconazole (400 mg and 800 mg daily) significantly increased plasma levels of terfenadine.<sup>2</sup><br><br>Fluconazole prescribing information states that the combined use of fluconazole at doses of 400 mg or greater with terfenadine is contraindicated.<sup>2</sup> The coadministration of fluconazole at doses lower than 400 mg/day with terfenadine should be carefully monitored.<sup>2</sup><br><br>The mechanism of this interaction is likely due to fluconazole-mediated inhibition of CYP3A4, an enzyme responsible for terfenadine metabolism.<sup>2</sup> Additionally, both fluconazole and terfenadine have been associated with QT-prolongation and their effects on the QT interval may be additive.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Honig PK, Wortham DC, Zamani K, Mullin JC, Conner DP, Cantilena LR. The effect of fluconazole on the steady-state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans. <i>Clin Pharmacol Ther</i>. 1993;53(6):630-636. [Pubmed ID 8513654]</p>\n<p>2. Diflucan (fluconazole) [prescribing information]. New York, NY: Pfizer Inc; September 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11686":"<p><b>Title</b> Vaccines (Live) / Axicabtagene Ciloleucel</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Axicabtagene Ciloleucel may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of infection may be increased. Axicabtagene Ciloleucel may diminish the therapeutic effect of Vaccines (Live). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid live virus vaccines for at least 6 weeks prior to initiation of lymphodepleting therapy, during axicabtagene ciloleucel infusion, and after treatment until full immune recovery is achieved.</p>\n<div>\n <p><b>Vaccines (Live) Interacting Members</b> Adenovirus (Types 4, 7) Vaccine, BCG Vaccine (Immunization), Cholera Vaccine, Influenza Virus Vaccine (Live/Attenuated), Japanese Encephalitis Virus Vaccine (Live/Attenuated), Measles, Mumps, and Rubella Virus Vaccine, Measles, Mumps, Rubella, and Varicella Virus Vaccine, Poliovirus Vaccine (Live/Bivalent/Oral), Poliovirus Vaccine (Live/Trivalent/Oral), Rotavirus Vaccine, Smallpox Vaccine Live, Typhoid Vaccine, Varicella Virus Vaccine, Yellow Fever Vaccine, Zoster Vaccine (Live/Attenuated)</p>\n</div> \n<p><b>Discussion</b> Live virus vaccines should be avoided for 6 weeks prior to initiation of lymphodepleting therapy, during axicabtagene ciloleucel infusion, and after treatment until full immune recovery is achieved.<sup>1</sup> The specific mechanism for this possible interaction is not clear, but axicabtagene ciloleucel treatment has been associated with B-cell aplasia and hypogammaglobulinemia, so it is possible that patients will be unable to mount a full immune response to live vaccines given concurrently.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Yescarta (axicabtagene ciloleucel) [prescribing information]. Santa Monica, CA: Kite Pharma, Inc; October 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11687":"<p><b>Title</b> Axicabtagene Ciloleucel / Corticosteroids (Systemic)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: Corticosteroids should not be used for premedication, but corticosteroids are indicated and may be required for treating toxicities associated with axicabtagene ciloleucel therapy.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Corticosteroids (Systemic) may diminish the therapeutic effect of Axicabtagene Ciloleucel. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid use of corticosteroids as premedication before treatment with axicabtagene ciloleucel. Corticosteroids are indicated and may be required for treatment of toxicities such as cytokine release syndrome or neurologic toxicity.</p>\n<div>\n <p><b>Corticosteroids (Systemic) Interacting Members</b> Beclomethasone (Systemic), Betamethasone (Systemic), Corticotropin, Cortisone, Deflazacort, Dexamethasone (Systemic), Fludrocortisone, Hydrocortisone (Systemic), MethylPREDNISolone, PrednisoLONE (Systemic), PredniSONE, Triamcinolone (Systemic)</p>\n</div> \n<p><b>Discussion</b> Although specific data regarding this potential interaction are not available, based on the immune-stimulating activity of axicabtagene ciloleucel, it is possible that concurrent use of drugs that suppress the immune system, such as systemic corticosteroids, may interfere with the clinical activity of axicabtagene ciloleucel.<sup>1</sup> Corticosteroids may be required to treat cytokine release syndrome or neurologic toxicity, but according to the axicabtagene ciloleucel prescribing information, corticosteroids should not be used as prophylactic therapy.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Yescarta (axicabtagene ciloleucel) [prescribing information]. Santa Monica, CA: Kite Pharma, Inc; October 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11688":"<p><b>Title</b> Astemizole / Fluconazole</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Fluconazole may enhance the QTc-prolonging effect of Astemizole. Fluconazole may increase the serum concentration of Astemizole. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of fluconazole and astemizole. This combination is listed as contraindicated in fluconazole product labeling.</p> \n<p><b>Discussion</b> Fluconazole prescribing information states that concomitant administration of fluconazole with astemizole may lead to increased plasma concentrations of astemizole, which can lead to QT prolongation and torsade de pointes.<sup>1</sup> Coadministration of fluconazole and astemizole is contraindicated.<sup>1</sup><br><br>The mechanism of this interaction is likely due to fluconazole-mediated inhibition of CYP3A4, an enzyme responsible for astemizole metabolism.<sup>2</sup> Additionally, both fluconazole and astemizole have been associated with QT-prolongation and their effects on the QT interval may be additive.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Diflucan (fluconazole) [prescribing information]. New York, NY: Pfizer Inc; September 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11689":"<p><b>Title</b> Olaparib / Ciprofloxacin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ciprofloxacin (Systemic) may increase the serum concentration of Olaparib. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for increased olaparib effects/toxicities if combined with ciprofloxacin. Consider reducing the dose of olaparib to 150 mg twice daily.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 57 patients with solid tumors, the strong CYP3A4 inhibitor itraconazole (200 mg daily for 7 days) increased the olaparib (100 mg single dose) AUC and maximum serum concentration 2.7-fold and 1.4-fold, respectively.<sup>1,2</sup> Pharmacokinetic models predict that use of the moderate CYP3A4 inhibitor fluconazole would increase the olaparib AUC 2.2-fold.<sup>2</sup><br><br>The olaparib prescribing information states that concurrent use of olaparib and moderate CYP3A4 inhibitors should be avoided when possible, but if such a combination cannot be avoided, the olaparib dose should be reduced to 150 mg twice daily.<sup>2</sup> Although olaparib product labeling lists ciprofloxacin as an example of a moderate CYP3A4 inhibitor,<sup>2</sup> the majority of clinical data suggests that ciprofloxacin is a weak CYP3A4 inhibitor.<sup>3,4</sup><br><br>Olaparib is a substrate for CYP3A4, so the likely mechanism for this interaction is inhibition of the CYP3A4-mediated metabolism of olaparib.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Dirix L, Swaisland H, Verheul HM, et al. Effect of itraconazole and rifampin on the pharmacokinetics of olaparib in patients with advanced solid tumors: results of two phase I open-label studies. <i>Clin Ther</i>. 2016;38(10):2286-2299. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27745744\">[PubMed 27745744]</a></p>\n<p>2. Lynparza (olaparib) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; January 2018.</p>\n<p>3. Sriwiriyajan S, Samaeng M, Ridtitid W, Mahatthanatrakul W, Wongnawa M. Pharmacokinetic interactions between ciprofloxacin and itraconazole in healthy male volunteers. <i>Biopharm Drug Dispos</i>. 2011;32(3):168-174. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21360715\">[PubMed 21360715]</a></p>\n<p>4. Shahzadi A, Javed I, Aslam B, et al. Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers. <i>Pak J Pharm Sci</i>. 2011;24(1):63-68. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21190921\">[PubMed 21190921]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11690":"<p><b>Title</b> Antiplatelet Agents (P2Y12 Inhibitors) / FentaNYL</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> FentaNYL may diminish the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). FentaNYL may decrease the serum concentration of Antiplatelet Agents (P2Y12 Inhibitors). <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> The clinical risk associated with this interaction has not been fully investigated and may vary with dose, regimen, timing, patient population, concomitant pharmacotherapy, or other factors. Monitor patients with acute coronary syndromes who are treated simultaneously with multiple antiplatelet agents (eg, aspirin, glycoprotein Iib/IIIa receptor antagonists) and/or an anticoagulant (eg, bivalirudin, enoxaparin, fondaparinux, heparin; these drugs may or may not provide adequate anticoagulant/antiplatelet coverage when P2Y12 inhibitor effects are delayed or attenuated. Due to a delay in platelet inhibition and absorption, one study recommends that routine use of fentanyl be discouraged during percutaneous coronary intervention (PCI) treatment in the absence of pain.</p>\n<div>\n <p><b>Antiplatelet Agents (P2Y12 Inhibitors) Interacting Members</b> Cangrelor, Clopidogrel, Prasugrel, Ticagrelor, Ticlopidine</p>\n</div> \n<p><b>Discussion</b> The PACIFY trial found that subjects receiving fentanyl had a lower ticagrelor AUC and less inhibition of platelet aggregation than those not receiving fentanyl.<sup>1</sup> The ticagrelor AUC was an average of 36.2% lower in those who received fentanyl, and platelet aggregation was approximately 43% to 44% higher, according to two separate measures of platelet function. Substantially more of those receiving fentanyl had a 2-hour platelet function measure indicating high on-treatment platelet reactivity (20% to 33% vs. 5% to 6%). By 4 hours, platelet aggregation values were similar in both arms. Self-reported pain was not significantly higher in the no-fentanyl arm of the study. This trial randomized 212 participants to receive IV fentanyl or no fentanyl during elective coronary angiography, 70 of whom were determined to require PCI and were loaded with ticagrelor (180 mg). All other drug dosing in the study was at the discretion of the treating provider.<br><br>These findings are generally similar to those with the opioid morphine and P2Y12 inhibitors. Patients who received morphine (n=37) had a ticagrelor time to maximum concentration (Tmax) that was 2-fold greater (4 vs 2 hours), indicating slowed ticagrelor absorption, and a maximum serum concentration and 12-hour AUC that were 31% and 36% lower, respectively, than in patients who received placebo (n=37).<sup>2</sup> In addition, morphine administration resulted in a greater proportion of patients treated with a P2Y12 inhibitor having high on-treatment platelet reactivity (at all measured time points) compared with patients who received placebo. Somewhat similarly, IV morphine was associated with a delayed ticagrelor Tmax (by about 1 hour), a 22% to 23% lower ticagrelor AUC, and a 25% lower ticagrelor maximum serum concentration in a study of healthy volunteers (n=24).<sup>3</sup> However, ticagrelor antiplatelet actions were not significantly different with morphine according to several different measures of ticagrelor actions.<br><br>The mechanism of this interaction has not been fully investigated, but due to the prolongation of both the P2Y12 inhibitor Tmax and the time to reach maximal platelet inhibition, opioid-induced delays in gastric emptying may play a significant role in this interaction. Whether other mechanisms contribute, which other opiates would have similar effects, or if the use of an intravenous P2Y12 inhibitor (eg, cangrelor) would diminish this interaction, are unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. McEvoy JW, Ibrahim K, Kickler TS, et al. Effect of intravenous fentanyl on ticagrelor absorption and platelet inhibition among patients undergoing percutaneous coronary intervention: the PACIFY randomized clinical trial. <i>Circulation</i>. 2017. (Epub ahead of print). <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=29046319\">[PubMed 29046319]</a></p>\n<p>2. Kubica J, Kubica A, Jilma B, et al. Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors. <i>Int J Cardiol</i>. 2016;215:201-208. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27128531\">[PubMed 27128531]</a></p>\n<p>3. Hobl EL, Reiter B, Schoergenhofer C, et al. Morphine decreases ticagrelor concentrations but not its antiplatelet effects: a randomized trial in healthy volunteers. <i>Eur J Clin Invest</i>. 2016;46(1):7-14. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26449338\">[PubMed 26449338]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11691":"<p><b>Title</b> Dacarbazine / Fotemustine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Fotemustine may enhance the adverse/toxic effect of Dacarbazine. Specifically, the risk for pulmonary toxicity (adult acute respiratory distress syndrome) may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Do not administer fotemustine and dacarbazine simultaneously, particularly with high doses of dacarbazine. An interval of 1 week should be left between the last administration of fotemustine and the first day of a course of dacarbazine. Monitor patients closely for signs of pulmonary toxicity (acute respiratory distress syndrome).</p> \n<p><b>Discussion</b> Two clinical studies report pulmonary toxicity in patients with disseminated malignant melanoma receiving high doses of dacarbazine and fotemustine (cumulative doses of approximately 1500 mg/m2 and 300 mg/m2, respectively).<sup>1,2</sup> Fotemustine product information recommends avoiding the simultaneous administration of dacarbazine and fotemustine.<sup>3</sup> An interval of 1 week should be left between the last administration of fotemustine and the first day of a course of dacarbazine.<sup>3</sup><br> <br>In contrast, this toxicity has not been reported in other clinical trials where fotemustine and dacarbazine were coadministered at lower doses (separated by 4 hours or 24 hours).<sup>4,5,6,7,8,9,10,11,12,13</sup> <br><br>The mechanism of this interaction has not been fully evaluated but may be due to competition for glutathione, alterations of the glutathione transferase activity, a direct effect of the increased alkylating power at the DNA level due to O6 alkyltransferase inhibition by high-dose dacarbazine, or the possible role of cytokines.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Aamdal S, Gerard B, Bohman T, D'Incalci M. Sequential administration of dacarbazine and fotemustine in patients with disseminated malignant melanoma-an effective combination with unexpected toxicity. <i>Eur J Cancer</i>. 1992; 28(2-3):447-450. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1591062\">[PubMed 1591062]</a></p>\n<p>2. Lee SM, Margison GP, Woodcock AA, Thatcher N. Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma. <i>Br J Cancer</i>. 1993;67(6):1356-1660. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8512821\">[PubMed 8512821]</a></p>\n<p>3. Muphoran (fotemustine) [summary of product characteristics]. Victoria, Australia: Servier Labaratories; May 2015. </p>\n<p>4. Fazeny-Dorner B, Veitl M, Wenzel C. Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme. <i>Anticancer Drugs</i>. 2003;14(6):437-442. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12853885\">[PubMed 12853885]</a></p>\n<p>5. Fazeny-Dorner B, Veitl M, Wenzel C, et al. Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme. <i>Br J Cancer</i>. 2003;88(4):496-501. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12592361\">[PubMed 12592361]</a></p>\n<p>6. Seeber A, Binder M, Steiner A, Wolff K, Pehamberger H. Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine. <i>Eur J Cancer</i>. 1998;34(13):2129-2131. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10070323\">[PubMed 10070323]</a></p>\n<p>7. Avril MF, Bonneterre J, Cupissol D, et al. Fotemustine plus dacarbazine for malignant melanoma. <i>Eur J Cancer</i>. 1992;28A(11):1807-1811. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1389514\">[PubMed 1389514]</a></p>\n<p>8. Binder M, Winkler A, Dorffner R, Glebowski E, Wolff K, Pehamberger H. Fotemustine plus dacarbazine in advanced stage III malignant melanoma. <i>Eur J Cancer</i>. 1992;28A(11):1814-1816. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1389516\">[PubMed 1389516]</a></p>\n<p>9. Richard MA, Grobb JJ, Zarrour H, et al. Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma. <i>Melanoma Res</i>. 1988;8(2):170-174. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9610872\">[PubMed 9610872]</a></p>\n<p>10. Pontse L, Lopres M, Ribeiro M, Santos JG, Azevedo MC. Isolated limb perfusion with fotemustine after chemosensitization with dacarbazine in melanoma. <i>Melanoma Res</i>. 1998;7(5):417-319. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9429225\">[PubMed 9429225]</a></p>\n<p>11. Comella P, Daponte A, Casaretti R, et al. Fotemustine and dacarbazine plus recombinant interferon alpha 2a in the treatment of advanced melanoma. <i>Eur J Cancer</i>. 1997;33(8):1326-1329. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9301463\">[PubMed 9301463]</a></p>\n<p>12. Rixe O, Borel C, Paraiso D, et al. Fotemustine, dacarbazine, vindesine combination chemotherapy in advanced malignant melanoma: a phase II study of 43 patients. <i>Melanoma Res</i>. 1995;5(6):419-424. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8589616\">[PubMed 8589616]</a></p>\n<p>13. Chang J, Atkinson H, A'Hern R, Lorentzos A, Gore ME. A phase II study of the sequential administration of dacarbazine and fotemustine in the treatment of cerebral metastases from malignant melanoma. <i>Eur J Cancer</i>. 1994;30A(14):2093-2095. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7857710\">[PubMed 7857710]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11692":"<p><b>Title</b> Fosphenytoin-Phenytoin / Fotemustine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Fosphenytoin-Phenytoin may decrease the serum concentration of Fotemustine. Fotemustine may decrease the serum concentration of Fosphenytoin-Phenytoin. Specifically, fotemustine may decrease concentrations of orally administered phenytoin. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of fotemustine and fosphenytoin/phenytoin.</p>\n<div>\n <p><b>Fosphenytoin-Phenytoin Interacting Members</b> Fosphenytoin, Phenytoin</p>\n</div> \n<p><b>Discussion</b> No clinical studies describe the use of phenytoin with fotemustine. However, clinical studies describe reductions in phenytoin levels and breakthrough seizure activity in patients treated with carmustine, a similar agent to fotemustine, when combined with cytotoxic chemotherapy agents (eg, cisplatin, etoposide, methotrexate, and vinblastine) and oral phenytoin.<sup>1,2,3</sup> Significant decreases in phenytoin levels may occur as early as 2 days after administration of chemotherapy.<sup>2,3</sup> The average increase in daily phenytoin dose to maintain therapeutic concentrations was 41%,<sup>1</sup> and ranged between 20% and 300%.<sup>1,2</sup><br> <br>Fotemustine product labeling states that fotemustine may decrease gastrointestinal absorption of phenytoin and increase the risk for seizures.<sup>4</sup> Additionally, fotemustine product labeling states that phenytoin may increase the hepatic metabolism of fotemustine, leading to enhanced toxicity or loss of efficacy.<sup>4</sup> The combination of fotemustine and phenytoin is not recommended.<sup>4</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Grossman SA, Sheidler VR, Gilbert MR. Decreased phenytoin levels in patients receiving chemotherapy. <i>Am J Med</i>. 1989;87:505-510. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2683764\">[PubMed 2683764]</a></p>\n<p>2. Ghosh C, Lazarus HM, Hewlett JS, Creger RJ. Fluctuation of serum phenytoin concentrations during autologous bone marrow transplant for primary central nervous system tumors. <i>J Neurooncol</i>. 1992;12(1):25-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1311752\">[PubMed 1311752]</a></p>\n<p>3. Bollini P, Riva R, Albani F, et al. Decreased phenytoin level during antineoplastic therapy: a case report. <i>Epilepsia</i>. 1983;24(1):75-78. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6822234\">[PubMed 6822234]</a></p>\n<p>4. Muphoran (fotemustine) [summary of product characteristics]. Victoria, Australia: Servier Labaratories; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11693":"<p><b>Title</b> Yellow Fever Vaccine / Fotemustine</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Fotemustine may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk for vaccine-related disease may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of fotemustine and the yellow fever vaccine. While all live vaccines should be avoided during fotemustine therapy, the combination of fotemustine and the yellow fever vaccine is specifically contraindicated. Live vaccines should generally be avoided for at least 3 months after cessation of immunosuppressant therapy (ie, fotemustine).</p> \n<p><b>Discussion</b> Fotemustine product labeling states that the combination of fotemustine and yellow fever vaccine is contraindicated due to the risk of fatal systemic vaccine-induced disease.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Muphoran (fotemustine) [summary of product characteristics]. Victoria, Australia: Servier Labaratories; May 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11694":"<p><b>Title</b> Fotemustine / Valproate Products</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Valproate Products may enhance the adverse/toxic effect of Fotemustine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased hematologic toxicities (eg, neutropenia, thrombocytopenia) if fotemustine is combined with valproate products.</p>\n<div>\n <p><b>Valproate Products Interacting Members</b> Divalproex, Valproic Acid and Derivatives</p>\n</div> \n<p><b>Discussion</b> In a clinical study of high-grade glioma patients treated with fotemustine, cisplatin, and etoposide, hematologic toxicity (neutropenia or thrombocytopenia) occurred significantly more in patients treated with valproic acid compared with patients treated with alternative antiepileptic drugs (phenobarbital, carbamazepine, phenytoin) or no antiepileptic drug therapy (55% vs 19%).<sup>1</sup> Hematologic toxicities were also noted to be more severe and more prolonged in patients who received valproic acid.<sup>1</sup> Similar increases in hematologic toxicities were also seen when a related drug, lomustine, was combined with valproic acid.<sup>2</sup><br><br>The mechanism of this potential interaction is unknown. It is unclear if valproic acid increases fotemustine concentrations or if valproic acid enhances the hematologic toxicity of fotemustine via another mechanism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bourg V, Lebrun C, Chichmanian RM, Thomas P, Frenay M. Nitroso-urea-cisplatin-based chemotherapy associated with valproate: increase of haematologic toxicity. <i>Ann Oncol</i>. 2001;12(2):217-219. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11300327\">[PubMed 11300327]</a></p>\n<p>2. Oberndorfer S, Piribauer M, Marosi C, Lahrmann H, Hitzenberger P, Grisold W. P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. <i>J Neurooncol</i>. 2005;72(3):255-260. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15937649\">[PubMed 15937649]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11695":"<p><b>Title</b> Ruxolitinib / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of Ruxolitinib. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor patient response to ruxolitinib closely, particularly monitoring for evidence of reduced ruxolitinib response.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> The ruxolitinib AUC and maximum serum concentration (Cmax) were reduced by an average of 61% and 32%, respectively, with concurrent use of the strong CYP3A4 inducer rifampin.<sup>1</sup> The relative exposure to active metabolites of ruxolitinib were reportedly increased by approximately 100%. Another report descibes an average 71% reduction in ruxolitinib AUC and a 52% decrease in ruxolitinib Cmax with rifampin pretreatment (600 mg/day for 10 days).<sup>2</sup> In contrast to these reported reductions in ruxolitinib concentrations, ruxolitinib pharmacodynamics appear to be less substantially altered, with one study reporting only a 10% reduction in effect with rifampin pretreatment.<sup>2</sup><br><br>No routine dose modification of ruxolitinib is recommended with concurrent use of strong CYP3A4 inducers. Clinicians are advised to monitor patient response and adjust therapy as appropriate.<sup>1</sup><br><br>The likely mechanism for this apparent interaction is increased ruxolitinib metabolism, resulting from induction of the CYP3A4-mediated metabolism of ruxolitinib.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Jakafi (ruxolitinib) [prescribing information]. Wilmington, DE: Incyte Corporation; October 2017.</p>\n<p>2. Shi JG, Chen X, Emm T, et al. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. <i>J Clin Pharmacol</i>. 2012;52(6):809-818. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21602517\">[PubMed 21602517]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11696":"<p><b>Title</b> Ruxolitinib / CYP3A4 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ruxolitinib. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for evidence of an altered response to ruxolitinib.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Moderate) Interacting Members</b> Aprepitant, Conivaptan, Crizotinib, DilTIAZem, Dronedarone, Erythromycin (Systemic), Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Isavuconazonium Sulfate, Letermovir, Netupitant, Nilotinib, Ribociclib, Schisandra, Verapamil</p>\n</div> \n<p><b>Discussion</b> The ruxolitinib AUC and maximum serum concentration (Cmax) were increased by an average of 27% and 8%, respectively, with concurrent use of the moderate CYP3A4 inhibitor erythromycin (500 mg every 12 hours).<sup>1,2</sup> An accompanying pharmacodynamic analysis reported an average 20% decrease in ruxolitinib effects with concurrent erythromycin, a difference the authors described as being of unlikely clinical significance.<sup>1</sup> <br><br>The likely mechanism for this apparent interaction is inhibition of the CYP3A4-mediated metabolism of ruxolitinib.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Shi JG, Chen X, Emm T, et al. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. <i>J Clin Pharmacol</i>. 2012;52(6):809-818. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21602517\">[PubMed 21602517]</a></p>\n<p>2. Jakafi (ruxolitinib) [prescribing information]. Wilmington, DE: Incyte Corporation; October 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11697":"<p><b>Title</b> Belatacept / Antithymocyte Globulin (Equine)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antithymocyte Globulin (Equine) may enhance the adverse/toxic effect of Belatacept. Specifically, the risk for venous thrombosis of the renal allograft may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> A 12-hour interval between administration of these 2 agents is suggested if these agents are to be used concomitantly. Monitor for venous thrombosis of the renal allograft if belatacept is coadministered with antithymocyte globulin, particularly in patients with other risk factors for venous thrombosis.</p> \n<p><b>Discussion</b> The belatacept prescribing information states that in post-marketing experience, venous thrombosis of the renal allograft has occurred when the intial dose of antithymocyte globulin (given as immunosuppressive induction) was coadministered (at the same time or nearly the same time) with the first dose of belatacept in patients with other predisposing risk factors for thrombosis.<sup>1</sup> <br><br>The mechanism of this potential interaction is unknown. In a clinical trial where antithymocyte globulin was not used, allograft thrombosis leading to graft loss occurred more often in belatacept-treated patients compared with cyclosporine-treated patients (4% vs 1%),<sup>2</sup> making the role of a drug interaction versus merely an adverse effect of belatacept in cases of renal allograft thrombosis unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Nulojix (belatacept) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; November 2017.</p>\n<p>2. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). <i>Am J Transplant</i>. 2010;10(3):547-557. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20415898\">[PubMed 20415898]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11698":"<p><b>Title</b> Belatacept / Antithymocyte Globulin (Rabbit)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Antithymocyte Globulin (Rabbit) may enhance the adverse/toxic effect of Belatacept. Specifically, the risk for venous thrombosis of the renal allograft may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> A 12-hour interval between administration of these 2 agents is suggested if these agents are to be used concomitantly. Monitor for venous thrombosis of the renal allograft if belatacept is coadministered with antithymocyte globulin, particularly in patients with other risk factors for venous thrombosis.</p> \n<p><b>Discussion</b> The belatacept prescribing information states that in post-marketing experience, venous thrombosis of the renal allograft has occurred when the intial dose of antithymocyte globulin (given as immunosuppressive induction) was coadministered (at the same time or nearly the same time) with the first dose of belatacept in patients with other predisposing risk factors for thrombosis.<sup>1</sup> <br><br>The mechanism of this potential interaction is unknown. In a clinical trial where antithymocyte globulin was not used, allograft thrombosis leading to graft loss occurred more often in belatacept-treated patients compared with cyclosporine-treated patients (4% vs 1%),<sup>2</sup> making the role of a drug interaction versus merely an adverse effect of belatacept in cases of renal allograft thrombosis unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Nulojix (belatacept) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; November 2017.</p>\n<p>2. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). <i>Am J Transplant</i>. 2010;10(3):547-557. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20415898\">[PubMed 20415898]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11699":"<p><b>Title</b> Thioridazine / Rolapitant</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Rolapitant may increase the serum concentration of Thioridazine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of thioridazine and rolapitant. This combination is listed as contraindicated in rolapitant prescribing information.</p> \n<p><b>Discussion</b> Rolapitant prescribing information states that its use in combination with pimozide is contraindicated.<sup>1</sup> The suspected primary mechanism of interaction between these agents is rolapitant inhibition of CYP2D6-mediated pimozide metabolism, which could increase pimozide exposure and the risk of QT prolongation and/or torsades de pointe. Based on a study with dextromethorphan, a single 180 mg dose of rolapitant moderately inhibits CYP2D6 on the day of dosing and continues beyond 28 days post-dose.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Varubi (rolapitant) [prescribing information]. Waltham, MA: Tesaro Inc; October 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}